Bibliometric Analysis of Research on cervical cancer and miRNAs from 2010 to 2024: Research Trends, HotSpots, and Prospects

Bibliometric Analysis of Research on cervical cancer and miRNAs from 2010 to 2024: Research Trends, HotSpots, and Prospects | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Bibliometric Analysis of Research on cervical cancer and miRNAs from 2010 to 2024: Research Trends, HotSpots, and Prospects Cong Xu, Yonghong Xu, Guangming Wang This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6135216/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 7 You are reading this latest preprint version Abstract Background and Purpose MicroRNAs (miRNAs) play multifaceted roles in cervical cancer therapy, including regulating cancer progression, metastasis, drug resistance, HPV control, and metabolic alterations. This study aims to provide a comprehensive bibliometric analysis of the existing literature on miRNAs in cervical cancer, offering insights into research trends, key contributors, and emerging themes to guide future investigations and enhance therapeutic strategies. Method We conducted a systematic search of the Web of Science and PubMed database for literature on miRNAs in cervical cancer published between January 2010 and December 2024. A total of 4034 records were retrieved and analyzed using VOSviewer and CiteSpace software for bibliometric visualization and trend analysis. Results Over the past fifteen years, research on miRNA in cervical cancer showed a significant upward trend before 2020, and then gradually declined starting from 2021. The analysis reveals that Tang and Hua are the most active authors, and China is the most influential country. "Plos One" is the journal that publishes the most articles. Besides, Tianjin Medical University is the most productive institution. The top three high-frequency keywords are "cervical cancer", "expression" and "invasion". Recent keyword and literature analysis indicates that the most notable feature of the current research is the deep integration of basic research and clinical application. Particularly, the cross-integration of non-coding RNA network research with emerging technologies such as nanotechnology and artificial intelligence is promoting the precise diagnosis and treatment system of cervical cancer. These findings highlight the interest in understanding the miRNA-mediated pathways and their clinical significance in cervical cancer. Conclusion This bibliometric analysis provides a comprehensive overview of the research landscape on miRNAs in cervical cancer, identifying key contributors, institutions, and emerging trends. While the study does not predict the future direction of cervical cancer treatment, it offers valuable insights into the current state of research and potential areas for further exploration. The findings underscore the importance of continued investigation into miRNA mechanisms and their therapeutic applications to advance cervical cancer management. Bibliometrics cervical cancer VOSviewer miRNA CiteSpace Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Figure 9 Figure 10 1. Introduction Cervical cancer(CC)constitutes a significant cause of morbidity and mortality globally and is the second most prevalent cancer among women, representing 14.1% of all female cancers and accounting for 7.1% of cancer-related deaths, as per the latest statistics. Among them, Asia and Africa are the two regions with the highest incidence and mortality of cervical cancer. (Moore 2006 )( https://gco.iarc.fr/today/en/dataviz/pie-prevalence?reset=1 ) While incidence and mortality of cervical cancer have dramatically decreased in affluent countries over the past 50 years, the disease is still a major concern in developing nations, and medically underserved groups continue to have a high risk of getting cervical cancer.(Yuan et al. 2023 ) The underutilization of cervical cancer screening in these populations is one of the factors contributing to the higher risk. Through numerous clinical studies, it has been demonstrated that the treatment of early-stage cervical cancer should focus on significantly enhancing patients' quality of life (with particular emphasis on preserving reproductive function) and improving treatment accuracy while ensuring therapeutic efficacy. These advancements are primarily reflected in three key dimensions: the reduction of surgical extent, the minimization of invasive surgical techniques, and the precision of lymph node assessment.(Francoeur, Monk, and Tewari 2025 ) Even with these alarming figures, the intricate pathological processes and molecular elements of cervical cancer continue to be a major threat to human health. The financial burden of cervical cancer in the area can be significantly reduced through the initiation of HPV-based initial screenings, effective handling of positive test outcomes, enhanced health education, and amalgamation of diverse health services. Attaining extensive screening and adherence to treatment protocols can significantly lower the occurrence and death rate of cervical cancer. (Song et al. 2023 ; Vu et al. 2018 ; Zhao et al. 2022 ) MicroRNAs, known as miRNAs, are small non-coding RNAs that play regulatory roles in inhibiting or activating fundamental biological functions and cancer-related genes in humans. Increasing evidence suggests frequent dysregulation of miRNAs in cervical cancer. (Bañuelos-Villegas, Pérez-yPérez, and Alvarez-Salas 2021 )Innovative sequencing methods uncover a comprehensive view of the human transcriptome's makeup. MicroRNAs fulfill various roles in transcription, translation, and post-translation by interacting with lncRNAs, mRNAs, and cirRNAs. Previous research indicates miRNAs play a role in the development of various illnesses, such as breast cancer, prostate cancer, and cervical cancer. Hence, clarifying the function of miRNAs will enhance our comprehension of cervical cancer. miRNAs play a multifaceted role in cervical cancer, notably in its advancement, spread, resistance to treatment, regulation of HPV, and metabolic alteration. miRNAs hold as target molecules in the treatment and pioneering biomarkers for CC. Nonetheless, additional clinical research is required to enhance our comprehension of miRNAs' healing advantages in CC. (Heidari-Ezzati et al. 2024 ) Gaining a more profound insight into miRNA's role and patterns in cervical cancer studies aids scientists in comprehending fundamental, groundbreaking, and impactful research, and offers direction for emerging researchers in choosing research paths that hold promise and worth. Within this framework, our research aimed to perform an extensive bibliometric examination, enabling the identification of principal authors, organizations, scholarly articles, prevailing research directions and trends in miRNAs' role in cervical cancer development, collaborative trends among nations and journals, existing research focal points in existing literature, and prospective research directions in this field. (Zhang, Tan, et al. 2024 ) Two well-known visual analysis tools that bibliometric researchers can use to transform vast volumes of disorganized data into reliable and unbiased network maps are CiteSpace and VOSviewer. (Jiang et al. 2024 ; Zheng et al. 2022 ; Yan et al. 2021 ) Through a methodical examination of miRNA and cervical cancer studies, our aim is to uncover knowledge voids, underscore crucial discoveries, and establish a robust groundwork for upcoming research to enhance our grasp of cervical cancer genetics and refine therapies. 2. Data and method 2.1 Data Policy and Screening Criteria We conducted a comprehensive literature search using the Web of Science (WOS) Core Collection and PubMed, widely recognized and authoritative databases known for its extensive coverage of high-quality, peer-reviewed research across multiple disciplines. Its robust indexing and citation tracking capabilities make it particularly suitable for bibliometric analyses. The search focused on articles published between 2010 and 2024, as this period aligns with significant advancements in miRNA research and sequencing technologies, which have greatly expanded the understanding of miRNAs in cervical cancer. Earlier publications were excluded to ensure the analysis reflects the most recent and relevant scientific developments. The search strategy employed the following formula: #1 ((ALL=(microRNA)) OR ALL=(miRNA)) OR TS=(mir))#2 ((ALL=(cervical cancer)) OR ALL=(cervical carcinoma)) OR ALL=(Carcinoma of Cervix)༉; #3: #1 AND #2. To ensure data accuracy and relevance, strict inclusion and exclusion criteria were applied. Only original research articles categorized as "article" were included, while reviews, conference papers, book chapters, editorial materials, and retracted publications were excluded. After applying these criteria, a total of 4034 documents were retrieved, downloaded, and stored in text format for further analysis. A comprehensive illustration of the research data collection process is presented in the data collection flowchart (Fig. 1 ). 2.2 Methods Bibliometric analysis is a quantitative method that uses mathematical and statistical techniques to examine patterns, trends, and relationships within academic literature. For this study, we employed two widely used tools: CiteSpace and VOSviewer. These tools were selected for their complementary strengths in visualizing and analyzing bibliometric networks, enabling a comprehensive exploration of research trends and collaborations. VOSviewer is software for constructing and visualizing bibliometric networks. It represents entities such as countries, institutions, journals, authors, and keywords as nodes, with the size of each node reflecting its frequency or importance. Lines connecting nodes indicate co-occurrence or collaboration between entities. This tool is particularly effective for mapping large datasets and identifying key themes and clusters within the literature. CiteSpace is another powerful tool for analyzing and visualizing trends in scientific literature. It uses algorithms to detect emerging trends, citation bursts, and thematic evolution over time. CiteSpace was chosen for its ability to generate dynamic visualizations of research landscapes, highlighting the temporal development of key topics and the influence of seminal works. Together, these tools provide a robust framework for understanding the structure and evolution of miRNA research in cervical cancer. Finally, the volume and details of the publications were analyzed and charted using Microsoft Office Excel to supplement the visual and quantitative insights generated by CiteSpace and VOSviewer. 3. Result 3.1 Outputs of Publications Evaluating the advancement of miRNA analysis in cervical cancer studies involved reviewing the publication records of 4034 WoSCC studies spanning 2010 to 2024, with the yearly publication data depicted in Fig. 2 . Generally, scholarly works indicate an expanding yet unpredictable pattern. Beginning in 2010 (n = 56), there was a rise and zenith in the quantity of studies in 2020 (n = 537), followed by a decrease in 2021 (n = 478). Commencing in 2021, there was a steady annual decrease in the quantity of studies. (Figure 2 ) 3.2 Density visualization of journals The data analysis showed that Plos One and Scientific Reports had the highest number of publications in miRNA and cervical cancer research (n = 114 and n = 91, respectively), but Scientific Reports had relatively low total link strength (8108) and citations (1066). It shows that the influence of his article is limited. Oncology Letters (n = 78) and Molecular Medicine Reports (n = 65) showed very high total link strength (23,150 and 16,356, respectively), indicating that they occupy a central position in the miRNA research network. Although the number of citations (1394 and 1210) is not the highest. It is worth noting that Oncotarget (n = 75), despite having been kicked out of the SCI, still shows a high number of citations (1771), reflecting its historical impact. Although Cell Death & Disease and BMC Cancer have fewer publications (n = 65 and n = 59, respectively), their studies may be of more reference value due to the high quality of the journals. Overall, Plos One, Oncotarget (historical data), and Biochemical and Biophysical Research Communications stand out in terms of impact, Oncology Letters, Oncology Reports and Molecular Medicine Reports are important sources for tumor-related miRNA studies. (Figure. 3, Table 1) 3.3 Allocation of research according to country or region A multitude of countries and regions participated in the study to investigate the impact of miRNA on cervical cancer incidence. The table about this topic presents the top 10 regions/countries with the highest number of published research papers, including China (n = 2879), the United States (n = 421), India (n = 129), and Japan (n = 80). In terms of research influence, as measured by citation counts, China and the United States are at the forefront, with significantly higher citations compared to other countries. Specifically, China has accumulated 52,274 citations, the United States has garnered 7,080 citations, and India has received 1,823 citations. This demonstrates that a substantial number of researchers in China, the United States and India are actively engaged in exploring the role of miRNA in cervical cancer incidence (Fig. 4 ). This data analysis reveals significant differences in the patterns of international research collaboration: The United States shows a high efficiency of international cooperation, and its total link strength (n = 237) even exceeds that of China (n = 210), which has the largest number of papers published, indicating that American researchers are more inclined to establish high-quality international cooperation networks, and the average international cooperation strength per paper is 0.56, much higher than that of China (0.07), highlighting its position as a global research collaborative hub. Although China's research output is dominated by 2879 articles (68% of the total), the low link strength to article ratio (0.07) reflects that the research is still dominated by domestic teams. Among the medium-sized countries, Canada performs well, with only 49 articles but a link strength of 67 (average article 1.37), reflecting its highly open scientific research ecology. On the other hand, Japan showed a relatively isolated trend, with only 38 link strengths of 80 articles, which may be affected by language barriers or localization research preferences. These findings suggest that the influence of scientific research depends not only on the quantity of output, but also on the quality of international cooperation, and countries need to develop differentiated cooperation strategies according to their own characteristics: China needs to enhance the depth of international cooperation while maintaining its scale advantage, the United States should maintain its open cooperation mechanism, and the "small but fine" model of countries such as Canada is worth learning from. It should be noted that the total link strength only reflects the quantitative characteristics of cooperation, and the specific quality of cooperation needs to be further analyzed in combination with indicators such as citation influence. (Table 2) 3.4 Co-authorship and citation relationships of institutions The data presented in this table elucidates the differentiated research development models of leading medical colleges in China. In terms of research output, Zhengzhou University (n = 80), Sun Yat-sen University (n = 76), and Nanjing Medical University (n = 72) ranked as the top three institutions, demonstrating a significant advantage in research volume. Although Tianjin Medical University published only 60 papers, it ranked first with 2,857 citations, achieving an impressive average of 47.6 citations per article, which underscores its commitment to high-quality research. Regarding international cooperation, Sun Yat-sen University leads with a total link strength of 450, while Wuhan University (363) and Zhejiang University (364) also exhibit strong performance, reflecting the extensive international collaboration networks established by these institutions. Notably, Shandong University (n = 61; total link strenth: 306) and China Medical University (n = 58; total link strenth: 317) primarily focus on domestic cooperation for their research endeavors. Conversely, Fudan University (n = 57; total link strenth: 341) and Huazhong University of Science and Technology (n = 56 ; total link strenth: 330) maintain a moderate scale while achieving balanced development in both research quality and international cooperation. These distinctions not only highlight the strategic positioning of each university but also reveal the diversified landscape of China's medical research ecosystem. Zhengzhou University exemplifies the "scale-first" development path, Tianjin Medical University reflects the "quality-first" research orientation, and Sun Yat-sen University showcases the successful implementation of "international collaboration." Furthermore, the total link strength index effectively captures the level of engagement and hub status of each institution within the global scientific research network, providing a critical metric for assessing institutional internationalization. (Figure 5 , Table 3) 3.5 Research hotspots and evolutionary trends of miRNA in CC field We choose "keyword" as the node type. 736 keywords were found, and the top 15 with the highest frequency are cervical cancer (n = 839), expression (n = 981), invasion (n = 589), proliferation (n = 555), metastasis (n = 403), migration (n = 395), growth (n = 388), and microRNAs (n = 344), progression (n = 340), carcinoma (n = 334), apoptosis (n = 333), cell proliferation (n = 296), cells (n = 242), cancer (n = 230), and human papillomavirus (n = 227). In the keyword co-occurrence diagram, the larger the node, the higher the keyword co-occurrence frequency. (Fig. 6 ). Keywords are the values used to identify specific data items in the literature, which are mainly used to briefly and accurately describe the topic of the article. We can understand the characteristics and evolution trend of the publication by analyzing the changes of keywords. This cluster chart summarizes the top 10 popular key research questions in the field. Keywords are divided into 10 different categories: #0 long non-coding, #1 DNA methylation, #2 cell proliferation, #3 cell proliferation, #4 gene, #5 head and neck squamous cell carcinoma, #6 nasopharyngeal carcinoma, #7 noncoding RNA, #8 cervical squamous cell carcinoma, #9 down regulation. (Fig. 7 ). Through the diachronic analysis of the keywords of miRNA research in cervical cancer from 2010 to 2024, we can clearly observe the dynamic evolution of research hotspots. In the early stage (2010–2013), research focused on basic mechanism exploration. The high frequency of keywords such as "cervical cancer" (n = 1839), "expression" (n = 981), and "human papillomavirus" (n = 227) reflects the researchers' focus on miRNA expression profiles and their relationship with HPV infection. As the study progressed (2014–2017), the distribution of keywords showed a clear trend of clinical transformation. The frequency of biomarker" (n = 49) and "chemoresistance" (n = 29) was significantly increased, indicating that research focus had shifted to the development of diagnostic markers and therapeutic targets. It is worth noting that the prominent performance of keywords such as "epithelial mesenchymal transition" (n = 109) and "migration" (n = 395) has revealed the central role of the EMT mechanism in tumor progression. The data of the last five years (2018–2024) show the characteristics of multi-dimensional expansion. On the one hand, the rapid growth of non-coding RNA-related keywords such as "circular RNA" (n = 75) and "long noncoding RNA" (n = 53) reflects the rise of ceRNA regulatory network research. On the other hand, the emergence of emerging keywords such as "immune infiltration" (n = 7) and "oxidative stress" (n = 5) indicates the expansion of research into tumor microenvironment and systems biology. Of particular concern is the technology-driven keywords such as "machine learning" (n = 3) and "nanoparticles" (n = 3) that appear in 2023–2024, indicating the application prospects of artificial intelligence and nanomedicine in this field. (Figure 8 ) It can also be analyzed from the keyword highlight chart. In recent years, the field of cervical cancer research has shown obvious stage evolution characteristics, from the early molecular mechanism exploration to clinical transformation application. Through the systematic analysis of the bibliometric data from 2010 to 2024, this study found that the research hotspots in this field experienced three significant development stages: the initial basic exploration period (2010–2015) was characterized by broad spectrum keywords such as "cancer" (intensity 12.62) and "gene" (intensity 10.30). The subsequent technical development period (2016–2020) focused on regulatory mechanisms such as "overexpression" (intensity 9.54) and epigenetic markers "DNA methylation" (intensity 8.15). At present, it has entered the clinical conversion period (2021–2024), and with non-coding RNA research as the leading factor, the emergence intensity of "circular rna" has significantly increased from 8.83 in 2021 to 9.84 in 2022, with an annual growth rate of 11.4%, showing a strong momentum of development. Notably, "squamous cell carcinoma" showed the highest outburst intensity (15.57) between 2012 and 2016, reflecting the importance of HPV-associated squamous cell carcinoma mechanism research. Based on the prediction of the time series model, cervical cancer research in the next five years will focus on three directions: liquid biopsy technology combined with circRNA, spatial multi-omics integration research, and NCRNA-immunotherapy combination strategy. The development of these emerging fields is expected to promote the transformation of cervical cancer diagnosis and treatment mode from traditional morphological diagnosis to molecular typing and precision therapy, providing new opportunities to improve patient prognosis. (Figure 9 ) 3.6 Co-authorship A total of 18,068 authors contributed to the study of microRNAs (miRNAs) in cervical cancer. Among them, the top ten authors with the highest number of published papers were identified.(Table 4)Through the comprehensive analysis of the data in this table, it can be seen that Chinese research institutions occupy a quantitative advantage in the field of cervical cancer miRNA research, but there is still room for international cooperation and quality improvement. Tang Hua༈n = 50༉, Liu Min༈n = 48༉ and Li Xin༈n = 28༉from Tianjin Medical University formed the core research team, which has been cited 5444 times in total, and the cooperation intensity is 73, showing strong academic influence. Xie Xing༈n = 22༉ and Lu Weiguo༈n = 21༉from Zhejiang University have a small number of papers, but each paper has been cited more than 40 times and the cooperation intensity is as high as 110, showing high quality research results and extensive cooperation network. In contrast, although the cooperation intensity of Wang Wei༈n = 49༉from Guangzhou, was only 6, indicating that his research was relatively isolated. It is worth noting that Steenbergen༈n = 30༉ and Meijer༈n = 25༉, scholars at the University Medical Center of Amsterdam have been cited an average of 735 times and maintain a high international cooperation relationship with a cooperation intensity of 47, providing a potential cooperation example for Chinese scholars. These findings suggest that while maintaining high output, Chinese teams need to focus on strengthening cooperation and communication with top teams in Europe and the United States, especially supporting scholars with weak cooperation networks but high output (such as Wang Wei), in order to further improve research quality and international influence. The H-index analyses of the table reveals the characteristics of multi-level differences in scientific research influence. First of all, Wang Jing from Peking University Sixth Hospital took a significant lead with the H-index of 105, indicating that his research results have outstanding academic influence, which is far higher than Tang Hua (49), the second ranking, and Meijer (58), the third scholar from the Netherlands. It is worth noting that two international scholars, Meijer (58) and Steenbergen (51), have excellent H-index performance, which corresponds to their high international cooperation strength (Total link strength of 72 and 22, respectively), reflecting the positive role of international cooperation in enhancing academic influence. In contrast, although Wang Wei of Guangzhou Medical University and Li Xin of Tianjin Medical University had a high number of publications (49 and 28 respectively), the H-index was only 5 and 4. This phenomenon of "high yield and low citation" may be due to the clinical application characteristics of their research directions or the junior qualifications of scholars. It is particularly noteworthy that Xie Xing and Lu Weiguo, two scholars from Zhejiang University, achieved a high H-index (40 and 39) while maintaining a moderate number of publications (22 and 21), reflecting stable research quality and sustained influence. These differences not only reflect the difference of individual research characteristics of scholars, but also reveal the shaping effect of disciplinary characteristics and international cooperation degree on academic influence. It is suggested that further research should be carried out in combination with factors such as scholars' career length and subject field characteristics. Wang, Wei, Guangzhou Medical University (This table system shows the core authors in the field of cervical cancer miRNA research and their academic influence pattern. The representative academic research results are in-depth analysis of the regulatory mechanism and clinical significance of miR-497 and miR-221-3p in cervical cancer. Studies have shown that miR-497 is significantly down-regulated in cervical cancer, and its low expression level is closely related to tumor progression and poor prognosis. Mechanistically, miR-497 inhibits proliferation and metastasis of tumor cells and induces apoptosis by targeting IGF-1R. On the other hand, we demonstrated for the first time that the exosome miR-221-3p promotes lymphatic metastasis through the VASH1/ERK/AKT signaling pathway. These findings not only reveal new molecular mechanisms, but also provide potential novel biomarkers and therapeutic targets for the early diagnosis and targeted therapy of cervical cancer. (Zhou et al. 2019 ;Luo et al. 2013 ) Tang, Hua(n = 50)and Liu, Min (n = 48), experts from Tianjin Medical University, systematically explained that different miRNAs (miR-346/miR-214/miR-372) regulate the diversity of cervical cancer malignant phenotypes through unique molecular mechanisms, revealing the AGO2-mediated amplification effect of miRNA network (miR-346). Cancer inhibition pathways that directly target key molecules of the cell cycle (miR-372) or signaling pathway nodes (miR-214) have also been identified, and directions for optimization of therapeutic strategies based on these findings (such as specific RNAi systems) have been explored. These results provide a multi-level theoretical basis for molecular typing and precise treatment of cervical cancer. (Guo et al. 2015 ; Tian et al. 2011 ; Deng et al. 2007 ; Yang et al. 2009 ) The authors' joint effort is described by lines connecting nodes on a visual diagram. Tang Hua, Wang Wei and Liu Min ranked among the top three, indicating their lofty status in the research field. Small correlations were observed across different study groups, suggesting a lack of collaborative efforts among authors across numerous study subgroups. 3.7 Analysis of co-citations of highly cited literature A total of 4034 articles were included in the analysis. The table presents the data of 10 most influential literatures in the field of miRNA research, and evaluates and analyzes them from two dimensions: Citations and Total link strength. In terms of citations, Tie et al. 's 2010 study topped the list with 384 citations, showing the wide influence of the literature in the academic community; Zhang (2016) and Hu (2010) ranked second and third with 281 and 259 citations, respectively. Notably, three of the top five citations were published between 2010 and 2011, suggesting that this period could be an important breakthrough period for miRNA research.(Table 5) In terms of total link strength, Hu (2010) has the most outstanding performance with a value of 86, which far exceeds other literatures, indicating that this study has a strong correlation and pivotal role in academic networks. It is found that earlier studies (2010–2011) generally have higher link strength, such as Hu (2010), Wilting (2010), etc. This may reflect the widespread influence of these foundational works on subsequent research. Overall, the literature published in 2010–2011 occupies a core position in the field of miRNA research, and these groundbreaking works are not only highly cited, but also play a key role in the academic network. Among them, Hu Xiaoxiao (2010) published in Cancer Research entitled "A MicroRNA Expression Signature for Cervical Cancer Prognosis." The paper has been cited 259 times, making it the most cited article in the field. The second most-cited paper was Nehad M. (2011) "miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway" published on Cancer Research (n = 253). In addition, Saskia M. Wilting's (2010) article "Methylation-mediated silencing and tumor suppressive function of hsa-miR-124 in cervical cancer" was published on Molecular Cancer (n = 221). To further analyze the literature landscape, we used VOSviewer software to visualize the top 116 publications and their citation patterns. The visualization provides insights into the high-frequency and most influential articles in the field of cervical cancer and miRNA research, promoting a deeper understanding of key contributions to the field(Figure 10 ,Table 6) 4. Discussion Bibliometric analysis and scientific cartography have advanced significantly in recent years, reflecting the scientific community's growing interest in deriving insights from comprehensive assessments of research trends. Using bibliometric methods, our study explores the landscape of miRNA research in cervical cancer, highlighting key developments and trends in this field. Bibliometric analysis is valuable for identifying influential studies, mapping research networks, and providing a broad overview of the knowledge landscape within a specific domain. (Kang et al. 2023 ; Urasheva et al. 2024 ; Mutebi et al. 2022 ) This study is an original bibliometric analysis of 4034 publications on miRNAs in cervical cancer, published between 2010 and 2024. The analysis reveals a steady increase in research output over this period, with a peak in 2020 followed by a slight decline. The initial growth can be attributed to advancements in sequencing technologies and reduced costs, which facilitated miRNA research. The post-2020 decline may be linked to disruptions caused by the COVID-19 pandemic. The growing interest in miRNA research is driven by their potential roles in cervical cancer progression, diagnosis, and treatment, as well as the development of advanced molecular techniques. (Almobarak 2024 ) The average number of citations per article remains moderate, suggesting that this field holds significant potential for further exploration. Collaboration network analysis highlights the prominent role of Chinese institutions, which dominate in terms of publication volume. China, the United States, India, Japan, and Mexico are among the top five countries contributing to this field, both in terms of publications and citations. Leading Chinese institutions, such as Sun Yat-Sen University, Zhengzhou University, Shandong University, Nanjing Medical University, and Wuhan University, have made substantial contributions, reflecting the collaborative efforts of researchers in China. However, while Chinese institutions lead in productivity, the impact of research from other countries should not be overlooked, as they may produce fewer but more highly cited studies. Regarding journal quality, Oncology Letters and Molecular Medicine Reports are among the most active and influential journals in this field, providing valuable platforms for researchers to share their findings. Each country has made distinct contributions to the research on miRNA and cervical cancer, with China, the United States, and India being the three countries that have published the most studies and made the most significant contributions in this field. China has made remarkable progress in the field of cancer prevention and control, with the 5-year survival rate of cancer increasing from 30.9% in 2003–2005 to 40.5% in 2012–2015, mainly due to the national cancer screening program, the promotion of multidisciplinary collaborative diagnosis and treatment model, the clinical application of precision oncology technology, and the optimization of innovative drug research and development policies. (Weeden et al. 2023 )In order to continuously improve the level of cancer prevention and control, China has set the goal of raising the 5-year survival rate to 46.6% by 2030 through the Healthy China 2030 plan, and has adopted a series of measures, including improving the medical security system and promoting the accessibility of medical resources. (Lu et al. 2023 ) At the technical level, professional organizations such as the Chinese Society of Clinical Oncology (CSCO) and the Chinese Anti-Cancer Association (CACA) have actively formulated diagnosis and treatment norms, promoted precision medicine to become the clinical standard, and supported the research of rare tumors and the transformation and application of artificial intelligence technology.(Diagnosis and Treatment Guidelines For Colorectal Cancer Working Group 2019; Lu et al. 2023 ; Fang et al. 2024 ) However, China still faces social challenges in the field of cancer prevention and control, such as cultural attitudes (such as stigma and traditional filial piety affecting treatment decisions) and an aging population, which need to be addressed by strengthening popular science education and promoting preventive measures (such as tobacco control and vaccination). (Lu et al. 2023 ) ( http://www.csco.ac.cn/cat/1/show/2.html ) These comprehensive measures reflect China's systematic planning and firm determination to improve the level of cancer diagnosis and treatment. In addition, many Chinese scholars have conducted in-depth and continuous research on the diagnosis and treatment of cervical cancer in the direction of precision medicine and molecular biology, and certain achievements have been made in the research on miRNA in the direction of cervical cancer. For example, some scholars have found a new mechanism of miR-532-5p inhibiting tumor metastasis by regulating the accumulation of lipid drops (LDs): As a competitive RNA (ceRNA), LINC01410 adsorbs miR-532-5p and releases its inhibition of FASN, thereby promoting LDs accumulation and driving EMT and lymphangiogenesis. Moreover, the combination therapy of miR-532-5p and orlistat (FASN inhibitor) can significantly inhibit tumor growth and lymph node metastasis in vivo, providing a new basis for therapeutic strategies targeting the metabolism-metastasis axis. (Shang et al. 2022 ) In addition, some scholars have found that LINC00885 plays a carcinogenic function in CC by regulating the miR-3150b-3p/BAZ2A axis. These findings suggest that LINC00885 may be a potentially promising therapeutic target for patients with CC. (Liu et al. 2022 ) Some scholars have used novel methods to study the diagnosis of cervical cancer. Chen et al. developed a novel nucleic acid detection technology based on the split Cas12a system (SCas12a), which can detect miRNA and long RNA with high sensitivity without pre-amplification, and distinguish between mature miRNA and pre-miRNA. The system can specifically identify DNA and miRNA point mutations, and has been successfully applied to the detection of plasma miR-21 in cervical cancer patients. Combined with RPA, the sensitivity is up to amolar level, and HPV can be detected in clinical samples. (Chen et al. 2024 ) These unique and advanced diagnostic approaches make it possible to augment current precision oncology practices in treatment decisions. Similarly, the United States, which has a lot of research achievements in the direction of miRNA, may be caused by mechanism exploration and technological invention as well as the open exploration of big data. In recent years, the field of cancer research has made revolutionary progress, mainly reflected in the following aspects: first, the significant reduction in the cost of sequencing technology and the maturity of technologies such as single-cell RNA sequencing, so that we can deeply understand the tumor and its microenvironment at the molecular level; Second, interdisciplinary fusion (such as the combination of nanotechnology, semiconductors, and biomedicine) has led to new diagnostic tools that significantly improve the ability of cells to accurately regulate. (Kelley et al. 2014 ; Kwon, Dudani, and Bhatia 2017 ; Kwong et al. 2013 ; Jonas et al. 2015 ; Huang et al. 2015 ) More importantly, studies based on the Cancer Genome Atlas and others have found that RNA technologies (including RNA interference drugs, mRNA vaccines, and CRISPR-Cas9 gene editing) are breaking through the limitations of traditional therapies, combining with nanomaterial delivery systems to provide new therapeutic possibilities for 80% of previously "unpharmaceutical" cancer targets. Together, these technological advances form a complete closed loop from basic research to clinical translation and are reshaping the cancer diagnosis and treatment landscape.(Tabernero et al. 2013 ; Liu et al. 2023 ; Zhen et al. 2023 ; Ehrke-Schulz et al. 2020 ) The breakthrough of sequencing technology is particularly prominent, which can not only analyze multiple piece of information of tumor microenvironment at the same time, but also realize micro RNA and single-cell sequencing with the improvement of library technology, which provides valuable data for the comparative study before and after treatment. However, the emergence of massive heterogeneous data also brings standardization challenges, and there is an urgent need to establish unified data standards, electronic health system integration, and cloud data sharing. (Jaffee et al. 2017 ) In addition to technological development, the huge prevalence and burden of India, which ranks third in the number of publications, is also a very important reason to promote the development of miRNA and cervical cancer. It is the second most common cancer among women in India. In 2018, the World Health Organization (WHO) reported an estimated 96,922 new cases of cervical cancer in India, with 60,078 deaths, representing 16.5% of the global burden.(Arbyn et al. 2020 ) The most frequently cited is "A MicroRNA Expression Signature for Cervical Cancer Prognosis" published in Cancer Research. This study has made an important breakthrough in predicting the prognosis of cervical cancer. By analyzing 102 cervical cancer samples, the research team found for the first time that two microRNAs, miR-200a and miR-9, can constitute effective prognostic markers, and established corresponding prediction models. Further mechanism studies showed that miR-200a could inhibit the metastasis of cervical cancer cells by synergistically regulating multiple transfer-related genes. (Hu et al. 2010 ) The second most-cited article was published in Cancer Research in 2010 and entitled "MiR-218 inhibits gastric cancer invasion and metastasis by targeting Robo1 receptors." In this study, a dual miRNA prognostic model based on miR-200a and miR-9 was established for the first time by analyzing 102 cervical cancer samples, which is a difficult clinical problem to predict the prognosis of invasive cervical cancer. Studies have found that these two miRNAs can not only effectively predict patient survival, but also play a key regulatory role in the progression of cervical cancer: in particular, miR-200a regulates the motor metastasis ability of cancer cells by synergistically inhibiting multiple metastasis-related genes. (Tie et al. 2010 ) This study not only provides a new personalized prognostic assessment tool for cervical cancer (300,000 deaths per year worldwide), but also reveals the important value of miR-200a as a potential therapeutic target, providing a double breakthrough for improving the clinical diagnosis and treatment of cervical cancer. Provides a fundamental understanding of microrna biology, including their role in gene regulation and their impact on disease. The third most cited is "Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer" published in Molecular Cancer. This study demonstrated for the first time that hsa-miR-124 is silenced in cervical cancer due to DNA hypermethylation, and its methylation frequency significantly increased from 0% in normal tissue to 93% in cancer tissue. Mechanism studies showed that hsa-miR-124 inhibited the proliferation and migration of cancer cells by regulating the target gene IGFBP7, and demethylation treatment could restore its expression. The hsa-miR-124-1/-2 methylation detection protocol developed in this study showed good predictive value for cervical precancerous lesions. These findings not only reveal the key role of epigenetic regulation of hsa-miR-124 in the occurrence of cervical cancer, but also provide a new molecular marker for early diagnosis. (Wilting et al. 2010 ) In conclusion, miRNAs play a crucial role in cervical cancer biology, influencing key processes such as gene regulation, tumor progression, and treatment response. In recent years, the regulatory role of non-coding RNA in the occurrence and development of cervical cancer has received increasing attention. Studies have shown that miRNA-centered non-coding RNA regulatory networks (including lncRNA and circRNA) show important value in the clinical diagnosis and treatment of cervical cancer. MiRNAs play a key role in cervical cancer progression and treatment response. (Pedroza-Torres et al. 2014 ) For example, miR-200a and miR-9 can be used as biomarkers to predict radiotherapy sensitivity, while miR-421 and miR-23b/34a affect DNA damage response by regulating ATM/p53 pathway. (Hu et al. 2010 ) These findings suggest that miRNA is not only a potential target for cervical cancer treatment, but also its expression profile is expected to be used in clinical treatment decision-making. Further validation of these miRNA markers and development of targeted regulatory strategies are needed in the future. In addition, lncRNA (such as HOTAIR) and circRNA (such as CDR1as) can act as molecular sponges of miRNA to regulate the expression of downstream target genes through competitive binding. HOTAIR removes the inhibition of ZEB1 by adsorption of miR-23b-3p, promoting EMT and metastasis; CDR1as, by antagonizing miR-7, up-regulates EGFR expression and drives tumor proliferation. These findings not only revealed the key role of the lncRNA/circRNA-miRNA-mRNA regulatory axis in malignant phenotypes such as apoptosis escape, metastasis and spread of cervical cancer, but also provided new ideas for clinical practice. (Di Leva, Garofalo, and Croce 2014 ; Romero-Barrios et al. 2018 ) On the one hand, specific molecules in these regulatory networks, such as the circCDR1as/miR-7/EGFR pathway, are expected to be novel biomarkers for early diagnosis and subtype differentiation. On the other hand, dynamic monitoring of changes in these networks (such as HOTAIR/miR-23b-3p/ZEB1 fluctuations during treatment) can provide a basis for efficacy evaluation and resistance monitoring. Although the current complexity of ncRNA interactions poses challenges for clinical translation, these findings are expected to promote the development of precision diagnosis and treatment of cervical cancer in the future through multi-center validation of biomarkers and development of combined targeted therapy strategies (such as simultaneously targeting miRNAs and regulating Ncrnas). (Shen et al. 2020 ; Heidari-Ezzati et al. 2024 ) Future research should focus on elucidating the functional roles of miRNAs in cervical cancer and exploring their potential as diagnostic biomarkers and therapeutic targets. Such efforts could pave the way for improved clinical outcomes and more effective treatment strategies. (Virani et al. 2021 ; Zhang, Zheng, et al. 2024 ) Keyword analysis reveals the main themes and focus areas of miRNA and cervical cancer research. High-frequency keywords such as "expression" and "invasion". These mechanisms are essential for understanding the progression of cervical cancer and identifying potential therapeutic targets. The consistency between keyword trends and the research topics discussed in this study highlights the trends and hot spots for each stage of miRNA-based research in cervical cancer. In recent years, cervical cancer miRNA research has shown a significant trend from the basic mechanism to clinical transformation. Earlier studies (2010–2013) focused on miRNA expression profiles and their association with HPV infection. The high-frequency keywords in this period were cervical cancer, expression, apoptosis, and HPV. Some scholars have investigated the characteristics of miRNA expression profiles in cervical cancer, indicating that aberrant miRNA expression may play a critical role in the development of cervical cancer. By conducting microarray chip analysis on cancerous and adjacent tissues from 13 HPV16/18-positive cervical cancer patients, it was found that 18 miRNAs were significantly upregulated (≥ 2-fold) and 19 miRNAs were significantly downregulated (≤ 0.5-fold). Notably, these patients were infected with human papillomavirus (HPV) types 16 and/or 18. (Rao et al. 2012 ) HPV facilitates malignant transformation through miRNA reprogramming. Research has demonstrated that the expression of 31 miRNAs undergoes continuous changes during the progression of cervical cancer. Among these, miR-29 suppresses cell proliferation and induces apoptosis by targeting YY1 (a transcription factor) and CDK6 (a cyclin-dependent kinase). Furthermore, the HPV oncogenic proteins E6/E7 may indirectly promote cellular malignant transformation by inhibiting miR-29. (Li et al. 2011 ) As biomarkers and therapeutic targets, miRNA is a marker for clinical translation of miRNA and cervical cancer studies (2014–2017). At this time, the key words EMT, biomarker and chemoresistance are most used. At present, a substantial number of miRNAs can serve as potential targets for generating diverse biological profiles of cervical cancer cells. Some studies have demonstrated that the expression of miR-1246 is negatively correlated with both cervical cancer surgical outcomes and HPV16E6 infection status, indicating its potential utility as a diagnostic biomarker. (Yang et al. 2015 ) Furthermore, the expression profiles of a three-miRNA panel (hsa-miR-3154, hsa-miR-7-3p, and hsa-miR-600) have been established to predict patient survival. Specifically, hsa-miR-3154 and hsa-miR-7-3p are associated with poor prognosis and enriched in the mTOR signaling pathway, while hsa-miR-600 correlates with favorable prognosis and is enriched in the AMPK signaling pathway. (Zeng et al. 2018 ) For instance, the oncogenic lncRNA PVT1 suppresses the expression of miR-195 by enhancing H3K27me3 modification and competitive binding within the miR-195 promoter region, thereby modulating paclitaxel-induced epithelial-mesenchymal transition (EMT) and chemoresistance. (Shen, Cheng, and Wang 2017 ) Additionally, iASPP promotes EMT and cisplatin resistance through the upregulation of miR-20a in a p53-dependent manner, with its effects mediated via targeting FBXL5 and BTG3. (Xiong et al. 2017 ) The increased expression of serum miR-205, along with the discovery that miR-144 inhibits tumor proliferation and metastasis by targeting VEGFA/VEGFC, further expands the clinical application potential of miRNAs as therapeutic targets for cervical cancer diagnosis and treatment. (Tao et al. 2018 )These findings provide a critical theoretical foundation for elucidating the molecular mechanisms underlying cervical cancer and developing novel therapeutic strategies. During this period, numerous studies have explored the molecular mechanisms underlying cervical cancer (CCa) progression, lymph node metastasis (LNM), and treatment resistance. Many scholars have conducted in-depth research on this topic. These investigations have identified several key regulatory molecules and their associated signaling pathways. Research has demonstrated that fatty acid-binding protein FABP5 is highly expressed in LNM, reprograms fatty acid metabolism to activate NF-κB signaling, thereby promoting epithelial-mesenchymal transition (EMT) and lymphangiogenesis. Meanwhile, miR-144-3p has been shown to inhibit the pro-metastatic effects of FABP5, and the fatty acid metabolic inhibitor orlistat effectively blocks this process. (Zhang, Liao, et al. 2020 ) Additionally, miR-532-5p suppresses LNM by regulating lipid droplet (LD) accumulation, while its competing endogenous RNA (ceRNA), LINC01410, upregulates fatty acid synthase (FASN) by sequestering miR-532-5p. (Shang et al. 2022 ) The combination of LINC01410 and orlistat significantly inhibits tumor growth. In terms of non-coding RNA regulation, hsa_circ_0043280 functions as a tumor-suppressive circRNA by maintaining PAQR3 expression and inhibiting tumor metastasis through competitive binding to miR-203a-3p. (Zhang et al. 2021) Exosome-mediated delivery of miR-663b in the tumor microenvironment inhibits vinculin (VCL) expression and promotes angiogenesis, suggesting its potential as a target for anti-angiogenic therapy. (You et al. 2021 )Furthermore, lactic acid enhances the migration and invasion capabilities of HPV16-positive cervical cancer cells by upregulating miR-744 and partially downregulating the expression of the E6/E7 oncogenes via ARHGAP5 inhibition. (Li et al. 2019 ) Collectively, these findings not only elucidate critical molecular mechanisms driving cervical cancer progression but also propose innovative therapeutic strategies based on miRNA, circRNA, and metabolic regulation, providing a theoretical foundation and potential targets for improving the prognosis of patients with cervical cancer. It is worth noting that the emergence of keywords such as "immune infiltration" (2022) and "machine learning" (2024) in recent years reflects the application potential of multi-omics integration and artificial intelligence in precision medicine. These trends suggest that future studies need to further explore the regulatory role of miRNA in immunotherapy resistance and develop targeted intervention strategies based on nanodelivery systems. In this short period of time, the keywords with high frequency are immune infiltration, oxidative stress and machine learning. In the field of machine learning, several scholars have conducted in-depth research by integrating the GEO and TCGA databases. Using a multi-omics analysis approach, they systematically investigated the molecular mechanisms underlying cervical cancer. Specifically, weighted gene co-expression network analysis (WGCNA) was employed to identify common differentially expressed genes (DEGs) associated with inflammatory bowel disease (IBD) and cervical cancer. Key pathways such as organelle fission, nuclear envelope, protein kinase activity, and HTLV-1 infection were identified. (Nguyen et al. 2022 ) Key hub genes (CDK1, MAD2L1, CCNB1) showed high connectivity in PPI networks. Random forest analysis identified shared hub genes (NCAPH, UHRF1, CDCA2) between psoriasis and cervical cancer, enriched in mitosis and DNA methylation pathways. Immune infiltration was analyzed by CIBERSORT, while cMAP predicted potential drugs. Regulatory networks revealed miRNA/TF interactions with hub genes. (Liu et al. 2024 ) The machine learning model validated the diagnostic potential of these hub genes (accuracy > 0.90), providing a critical foundation for molecular classification and precision treatment of cervical cancer. In the realm of immunology, key mechanisms of immune escape mediated by non-coding RNA in cervical cancer have been elucidated. Research has demonstrated that long non-coding RNA LINC00240 is abnormally overexpressed in cervical cancer. Through competitive binding with miR-124-3p, it removes the inhibition of STAT3, further downregulating the expression of the natural killer (NK) cell activation ligand MICA. This leads to impaired cytotoxic function of NK T cells (NKT) and promotes tumor immune escape. Another long non-coding RNA, LINC01871, upregulates the expression of MAP3K2 and activates the MAPK signaling pathway by adsorbing miR-873-3p. (Li et al. 2025 ) Additionally, another study reveals that HPV16 oncogenic proteins E6/E7 remove their inhibitory effect on PD-L1 by downregulating miR-142-5p, thereby enhancing the immune escape capability of tumor cells. (Zhang, Li, et al. 2020 ) Overexpression of miR-142-5p effectively reverses this process and inhibits the growth of transplanted tumors. (Ling et al. 2022 ) These findings comprehensively disclose multiple immune escape pathways regulated by non-coding RNA in cervical cancer, offering important theoretical foundations and potential therapeutic targets for developing novel strategies in non-coding RNA-based immunotherapy. 5. Limitation This study presents a bibliometric analysis of a foundational paper focusing on the role of miRNAs in cervical cancer. It outlines the advancements in this field by conducting a quantitative review of existing scholarly literature, aiming to provide guidance for future academic research. However, it is essential to acknowledge certain limitations. First, the exclusive reliance on the PubMed and Web of Science databases for data collection may introduce publication bias, potentially excluding studies that yield important results but are published in languages other than English. Additionally, various valuable sources of information, such as books, case reports, clinical trials, and meta-analyses, might be overlooked. Since the analysis was finalized in December 2024, several recent studies with significant findings may have been omitted from this review. 6. Conclusion This bibliometric analysis offers a systematic and comprehensive overview of research trends and hotspots related to microRNAs (miRNAs) in cervical cancer (CC) from 2010 to 2024. The study underscores a substantial increase in research output, driven by advancements in sequencing technologies and an enhanced understanding of the role of miRNAs in the progression, diagnosis, and treatment of CC. Key findings reveal major contributors, including China, the United States, and prestigious institutions such as Tianjin Medical University, as well as influential journals like PLOS ONE and Molecular Medicine Reports. Keyword analysis highlights miRNA-mediated mechanisms, such as gene expression regulation, cancer cell proliferation, migration, and apoptosis, emphasizing their potential as therapeutic targets and diagnostic biomarkers. Despite these advancements, the translation of miRNA research into clinical applications remains limited. The relatively moderate citation rate of articles in this field indicates significant opportunities for further investigation. Future studies should focus on elucidating the functional roles of specific miRNAs in CC, validating their utility as diagnostic markers, and integrating novel research methodologies to develop miRNA-based therapies. Collaborative efforts among institutions and countries are crucial to overcoming existing challenges and advancing development in this area. This study not only provides a detailed depiction of the current state of miRNA research in CC but also establishes a foundation to guide future research and foster innovation for clinical applications. Abbreviations The following abbreviations are used in this manuscript: CC Cervical Cancer miRNA microRNA HPV Human Papillomavirus WOS Web of Science MSP Methylation-Specific PCR IGFBP7 Insulin-like Growth Factor Binding Protein 7 EMT Epithelial-Mesenchymal Transition lncRNA Long Non-coding RNA circRNA Circular RNA RT-PCR Reverse Transcription Polymerase Chain Reaction ISH In Situ Hybridization RPA Recombinase Polymerase Amplification MDT Multidisciplinary Team CACA Chinese Anti-Cancer Association CSCO Chinese Society of Clinical Oncology Declarations Contributions Data curation, C.X.,Y.X.; writing—original draft, C.X. ; software, C.X. ; writing—review & editing, C.X. and G.W.; resources, G.W. All authors have read and agreed to the published version of the manuscript. Funding Statement This work was supported by the Yunnan Province, Science and Technology Department of Yunnan Province (grant number 202001BA070001-133); the University Affiliated College, Key Construction Disciplines, 2021-2024, host, in research, 180,000; and the Joint Special Project of Local Universities of Yunnan Province (grant number 202001BA070001-156) ;Dali City Industrial Information and Science and Technology Bureau on the Dali City 2024 Science and Technology Plan project (grant number 2024KBG145) Conflict of interest There is no conflict of interest to disclose. Data Availability Statement The datasets generated during and analyzed during thecurrent study are publicly available. Ethical Statement: Given that all data originated from online databases, patients' written informed consent was secured. Moreover, our research relied on open-source data, eliminating any pertinent ethical concerns. References Almobarak, F. 2024. 'Bibliometric analysis of global research in palliative care for cervical cancer', Front Oncol , 14: 1432805. Arbyn, M., E. Weiderpass, L. Bruni, S. de Sanjosé, M. Saraiya, J. Ferlay, and F. Bray. 2020. 'Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis', Lancet Glob Health , 8: e191-e203. Bañuelos-Villegas, E. G., M. F. Pérez-yPérez, and L. M. Alvarez-Salas. 2021. 'Cervical Cancer, Papillomavirus, and miRNA Dysfunction', Front Mol Biosci , 8: 758337. Chen, Y., X. Wang, J. Zhang, Q. Jiang, B. Qiao, B. He, W. Yin, J. Qiao, and Y. Liu. 2024. 'Split crRNA with CRISPR-Cas12a enabling highly sensitive and multiplexed detection of RNA and DNA', Nat Commun , 15: 8342. Deng, W. G., G. Jayachandran, G. Wu, K. Xu, J. A. Roth, and L. Ji. 2007. 'Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells', J Biol Chem , 282: 26460-70. Di Leva, G., M. Garofalo, and C. M. Croce. 2014. 'MicroRNAs in cancer', Annu Rev Pathol , 9: 287-314. Diagnosis, and Csococ Treatment Guidelines For Colorectal Cancer Working Group. 2019. 'Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)', Chin J Cancer Res , 31: 117-34. Ehrke-Schulz, E., S. Heinemann, L. Schulte, M. Schiwon, and A. Ehrhardt. 2020. 'Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells', Cancers (Basel) , 12. Fang, W., Z. Yu, C. Chen, G. Chen, K. Chen, J. Fu, Y. Han, X. Fu, J. Wang, T. Mao, Z. Gu, and N. Xu. 2024. 'China Anti-Cancer Association Guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023)', Mediastinum , 8: 27. Francoeur, A. A., B. J. Monk, and K. S. Tewari. 2025. 'Treatment advances across the cervical cancer spectrum', Nat Rev Clin Oncol , 22: 182-99. Guo, J., J. Lv, M. Liu, and H. Tang. 2015. 'miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy', J Biol Chem , 290: 30342-50. Heidari-Ezzati, S., P. Moeinian, B. Ahmadian-Nejad, F. Maghbbouli, S. Abbasi, M. Zahedi, H. Afkhami, A. Shadab, and N. Sajedi. 2024. 'The role of long non-coding RNAs and circular RNAs in cervical cancer: modulating miRNA function', Front Cell Dev Biol , 12: 1308730. Hu, X., J. K. Schwarz, J. S. Lewis, Jr., P. C. Huettner, J. S. Rader, J. O. Deasy, P. W. Grigsby, and X. Wang. 2010. 'A microRNA expression signature for cervical cancer prognosis', Cancer Res , 70: 1441-8. Huang, L., A. Holtzinger, I. Jagan, M. BeGora, I. Lohse, N. Ngai, C. Nostro, R. Wang, L. B. Muthuswamy, H. C. Crawford, C. Arrowsmith, S. E. Kalloger, D. J. Renouf, A. A. Connor, S. Cleary, D. F. Schaeffer, M. Roehrl, M. S. Tsao, S. Gallinger, G. Keller, and S. K. Muthuswamy. 2015. 'Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids', Nat Med , 21: 1364-71. Jaffee, E. M., C. V. Dang, D. B. Agus, B. M. Alexander, K. C. Anderson, A. Ashworth, A. D. Barker, R. Bastani, S. Bhatia, J. A. Bluestone, O. Brawley, A. J. Butte, D. G. Coit, N. E. Davidson, M. Davis, R. A. DePinho, R. B. Diasio, G. Draetta, A. L. Frazier, A. Futreal, S. S. Gambhir, P. A. Ganz, L. Garraway, S. Gerson, S. Gupta, J. Heath, R. I. Hoffman, C. Hudis, C. Hughes-Halbert, R. Ibrahim, H. Jadvar, B. Kavanagh, R. Kittles, Q. T. Le, S. M. Lippman, D. Mankoff, E. R. Mardis, D. K. Mayer, K. McMasters, N. J. Meropol, B. Mitchell, P. Naredi, D. Ornish, T. M. Pawlik, J. Peppercorn, M. G. Pomper, D. Raghavan, C. Ritchie, S. W. Schwarz, R. Sullivan, R. Wahl, J. D. Wolchok, S. L. Wong, and A. Yung. 2017. 'Future cancer research priorities in the USA: a Lancet Oncology Commission', Lancet Oncol , 18: e653-e706. Jiang, N., T. Yang, H. Han, J. Shui, M. Hou, W. Wei, G. Kumar, L. Song, C. Ma, X. Li, and Z. Ding. 2024. 'Exploring Research Trend and Hotspots on Oxidative Stress in Ischemic Stroke (2001-2022): Insights from Bibliometric', Mol Neurobiol , 61: 6200-16. Jonas, O., H. M. Landry, J. E. Fuller, J. T. Santini, Jr., J. Baselga, R. I. Tepper, M. J. Cima, and R. Langer. 2015. 'An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors', Sci Transl Med , 7: 284ra57. Kang, M., J. Qiu, H. Wei, and J. Li. 2023. 'A bibliometric analysis of global research trends of inflammation in cervical cancer: A review', Medicine (Baltimore) , 102: e36598. Kelley, S. O., C. A. Mirkin, D. R. Walt, R. F. Ismagilov, M. Toner, and E. H. Sargent. 2014. 'Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering', Nat Nanotechnol , 9: 969-80. Kwon, E. J., J. S. Dudani, and S. N. Bhatia. 2017. 'Ultrasensitive tumour-penetrating nanosensors of protease activity', Nat Biomed Eng , 1. Kwong, G. A., G. von Maltzahn, G. Murugappan, O. Abudayyeh, S. Mo, I. A. Papayannopoulos, D. Y. Sverdlov, S. B. Liu, A. D. Warren, Y. Popov, D. Schuppan, and S. N. Bhatia. 2013. 'Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease', Nat Biotechnol , 31: 63-70. Li, C., L. Jia, Y. Yu, and L. Jin. 2019. 'Lactic acid induced microRNA-744 enhances motility of SiHa cervical cancer cells through targeting ARHGAP5', Chem Biol Interact , 298: 86-95. Li, Y., F. Wang, J. Xu, F. Ye, Y. Shen, J. Zhou, W. Lu, X. Wan, D. Ma, and X. Xie. 2011. 'Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29', J Pathol , 224: 484-95. Li, Y., L. Wei, H. H. Zhang, H. F. Ci, and D. J. Li. 2025. 'LINC01871 facilitates cervical cancer cell migration and immune escape by targeting miR-873-3p/MAP3K2 axis', Kaohsiung J Med Sci , 41: e12948. Ling, J., Q. Sun, Q. Tian, H. Shi, H. Yang, and J. Ren. 2022. 'Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis', Arch Biochem Biophys , 731: 109449. Liu, C., Q. Shi, X. Huang, S. Koo, N. Kong, and W. Tao. 2023. 'mRNA-based cancer therapeutics', Nat Rev Cancer , 23: 526-43. Liu, L., P. Yin, R. Yang, G. Zhang, C. Wu, Y. Zheng, S. Wu, and M. Liu. 2024. 'Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma', Front Immunol , 15: 1351908. Liu, Y., J. Chen, L. Zhou, and C. Yin. 2022. 'LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A', Biol Direct , 17: 4. Lu, Z., Y. Chen, D. Liu, X. Jiao, C. Liu, Y. Wang, Z. Zhang, K. Jia, J. Gong, Z. Yang, and L. Shen. 2023. 'The landscape of cancer research and cancer care in China', Nat Med , 29: 3022-32. Luo, M., D. Shen, X. Zhou, X. Chen, and W. Wang. 2013. 'MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor', Surgery , 153: 836-47. Moore, D. H. 2006. 'Cervical cancer', Obstet Gynecol , 107: 1152-61. Mutebi, M., G. Lewison, A. Aggarwal, O. I. Alatise, C. Booth, M. Cira, S. Grover, O. Ginsburg, J. Gralow, S. Gueye, B. Kithaka, T. P. Kingham, L. Kochbati, J. Moodley, S. I. Mohammed, A. Mutombo, N. Ndlovu, C. Ntizimira, G. P. Parham, F. Walter, J. Parkes, D. Shamely, N. Hammad, J. Seeley, J. Torode, R. Sullivan, and V. Vanderpuye. 2022. 'Cancer research across Africa: a comparative bibliometric analysis', BMJ Glob Health , 7. Nguyen, T. B., D. N. Do, M. L. Nguyen-Thi, H. Hoang-The, T. T. Tran, and T. Nguyen-Thanh. 2022. 'Identification of potential crucial genes and key pathways shared in Inflammatory Bowel Disease and cervical cancer by machine learning and integrated bioinformatics', Comput Biol Med , 149: 105996. Pedroza-Torres, A., E. López-Urrutia, V. García-Castillo, N. Jacobo-Herrera, L. A. Herrera, O. Peralta-Zaragoza, C. López-Camarillo, D. C. De Leon, J. Fernández-Retana, J. F. Cerna-Cortés, and C. Pérez-Plasencia. 2014. 'MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance', Molecules , 19: 6263-81. Rao, Q., Q. Shen, H. Zhou, Y. Peng, J. Li, and Z. Lin. 2012. 'Aberrant microRNA expression in human cervical carcinomas', Med Oncol , 29: 1242-8. Romero-Barrios, N., M. F. Legascue, M. Benhamed, F. Ariel, and M. Crespi. 2018. 'Splicing regulation by long noncoding RNAs', Nucleic Acids Res , 46: 2169-84. Shang, C., Y. Li, T. He, Y. Liao, Q. Du, P. Wang, J. Qiao, and H. Guo. 2022. 'The prognostic miR-532-5p-correlated ceRNA-mediated lipid droplet accumulation drives nodal metastasis of cervical cancer', J Adv Res , 37: 169-84. Shen, C. J., Y. M. Cheng, and C. L. Wang. 2017. 'LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells', J Drug Target , 25: 637-44. Shen, S., S. Zhang, P. Liu, J. Wang, and H. Du. 2020. 'Potential role of microRNAs in the treatment and diagnosis of cervical cancer', Cancer Genet , 248-249: 25-30. Song, L., X. Liang, M. Zhu, Q. Su, and F. Li. 2023. 'Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023)', Front Immunol , 14: 1328103. Tabernero, J., G. I. Shapiro, P. M. LoRusso, A. Cervantes, G. K. Schwartz, G. J. Weiss, L. Paz-Ares, D. C. Cho, J. R. Infante, M. Alsina, M. M. Gounder, R. Falzone, J. Harrop, A. C. White, I. Toudjarska, D. Bumcrot, R. E. Meyers, G. Hinkle, N. Svrzikapa, R. M. Hutabarat, V. A. Clausen, J. Cehelsky, S. V. Nochur, C. Gamba-Vitalo, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, and H. A. Burris, 3rd. 2013. 'First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement', Cancer Discov , 3: 406-17. Tao, P., H. Wen, B. Yang, A. Zhang, X. Wu, and Q. Li. 2018. 'miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC', Exp Ther Med , 15: 562-68. Tian, R. Q., X. H. Wang, L. J. Hou, W. H. Jia, Q. Yang, Y. X. Li, M. Liu, X. Li, and H. Tang. 2011. 'MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis', J Biol Chem , 286: 25556-63. Tie, J., Y. Pan, L. Zhao, K. Wu, J. Liu, S. Sun, X. Guo, B. Wang, Y. Gang, Y. Zhang, Q. Li, T. Qiao, Q. Zhao, Y. Nie, and D. Fan. 2010. 'MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor', PLoS Genet , 6: e1000879. Urasheva, Z. U., G. B. Kabdrakhmanova, A. P. Yermagambetova, A. B. Utegenova, N. A. Seitmaganbetova, O. M. Aliyev, S. S. Kurmangaliyeva, N. K. Kenzhina, Y. Z. Kurmambayev, and A. A. Khamidulla. 2024. 'Bibliometric Analysis of the Role of Occludin in the Pathogenesis of Stroke', Oxid Med Cell Longev , 2024: 2121733. Virani, S. S., A. Alonso, H. J. Aparicio, E. J. Benjamin, M. S. Bittencourt, C. W. Callaway, A. P. Carson, A. M. Chamberlain, S. Cheng, F. N. Delling, M. S. V. Elkind, K. R. Evenson, J. F. Ferguson, D. K. Gupta, S. S. Khan, B. M. Kissela, K. L. Knutson, C. D. Lee, T. T. Lewis, J. Liu, M. S. Loop, P. L. Lutsey, J. Ma, J. Mackey, S. S. Martin, D. B. Matchar, M. E. Mussolino, S. D. Navaneethan, A. M. Perak, G. A. Roth, Z. Samad, G. M. Satou, E. B. Schroeder, S. H. Shah, C. M. Shay, A. Stokes, L. B. VanWagner, N. Y. Wang, and C. W. Tsao. 2021. 'Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association', Circulation , 143: e254-e743. Vu, M., J. Yu, O. A. Awolude, and L. Chuang. 2018. 'Cervical cancer worldwide', Curr Probl Cancer , 42: 457-65. Weeden, C. E., W. Hill, E. L. Lim, E. Grönroos, and C. Swanton. 2023. 'Impact of risk factors on early cancer evolution', Cell , 186: 1541-63. Wilting, S. M., R. A. van Boerdonk, F. E. Henken, C. J. Meijer, B. Diosdado, G. A. Meijer, C. le Sage, R. Agami, P. J. Snijders, and R. D. Steenbergen. 2010. 'Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer', Mol Cancer , 9: 167. Xiong, Y., F. Sun, P. Dong, H. Watari, J. Yue, M. F. Yu, C. Y. Lan, Y. Wang, and Z. B. Ma. 2017. 'iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling', J Exp Clin Cancer Res , 36: 48. Yan, W. T., S. Lu, Y. D. Yang, W. Y. Ning, Y. Cai, X. M. Hu, Q. Zhang, and K. Xiong. 2021. 'Research trends, hot spots and prospects for necroptosis in the field of neuroscience', Neural Regen Res , 16: 1628-37. Yang, Y., Y. J. Xie, Q. Xu, J. X. Chen, N. C. Shan, and Y. Zhang. 2015. 'Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance', Gynecol Oncol , 138: 683-8. Yang, Z., S. Chen, X. Luan, Y. Li, M. Liu, X. Li, T. Liu, and H. Tang. 2009. 'MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells', IUBMB Life , 61: 1075-82. You, X., W. Sun, Y. Wang, X. Liu, A. Wang, L. Liu, S. Han, Y. Sun, J. Zhang, L. Guo, and Y. Zhang. 2021. 'Cervical cancer-derived exosomal miR-663b promotes angiogenesis by inhibiting vinculin expression in vascular endothelial cells', Cancer Cell Int , 21: 684. Yuan, M., X. Zhao, H. Wang, S. Hu, and F. Zhao. 2023. 'Trend in Cervical Cancer Incidence and Mortality Rates in China, 2006-2030: A Bayesian Age-Period-Cohort Modeling Study', Cancer Epidemiol Biomarkers Prev , 32: 825-33. Zeng, Y., K. X. Wang, H. Xu, and Y. Hong. 2018. 'Integrative miRNA analysis identifies hsa-miR-3154, hsa-miR-7-3, and hsa-miR-600 as potential prognostic biomarker for cervical cancer', J Cell Biochem , 119: 1558-66. Zhang, C., Y. Liao, P. Liu, Q. Du, Y. Liang, S. Ooi, S. Qin, S. He, S. Yao, and W. Wang. 2020. 'FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism', Theranostics , 10: 6561-80. Zhang, C., P. Liu, J. Huang, Y. Liao, C. Pan, J. Liu, Q. Du, T. Liu, C. Shang, S. Ooi, R. Chen, M. Xia, H. Jiang, M. Xu, Q. Zou, Y. Zhou, H. Huang, Y. Pan, L. Yuan, W. Wang, and S. Yao. 2021. 'Circular RNA hsa_circ_0043280 inhibits cervical cancer tumor growth and metastasis via miR-203a-3p/PAQR3 axis', Cell Death Dis , 12: 888. Zhang, M., Z. Zheng, S. Wang, R. Liu, M. Zhang, Z. Guo, H. Wang, and W. Tan. 2024. 'The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer', Cancer Drug Resist , 7: 30. Zhang, Y., X. Li, J. Zhang, and H. Liang. 2020. 'Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis', Cancer Lett , 474: 63-73. Zhang, Y., Y. T. Tan, M. J. Wang, L. Li, J. F. Huang, and S. C. Wang. 2024. 'Bibliometric analysis of PTEN in neurodevelopment and neurodegeneration', Front Aging Neurosci , 16: 1390324. Zhao, S., L. Huang, P. Basu, E. J. Domingo, W. Supakarapongkul, W. Y. Ling, D. Ocviyanti, R. Rezhake, Y. Qiao, E. H. Tay, and F. Zhao. 2022. 'Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries', Cancer Lett , 525: 22-32. Zhen, S., R. Qiang, J. Lu, X. Tuo, X. Yang, and X. Li. 2023. 'CRISPR/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer', J Med Virol , 95: e28144. Zheng, S. Y., X. M. Hu, K. Huang, Z. H. Li, Q. N. Chen, R. H. Yang, and K. Xiong. 2022. 'Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going', Front Surg , 9: 1025557. Zhou, C. F., J. Ma, L. Huang, H. Y. Yi, Y. M. Zhang, X. G. Wu, R. M. Yan, L. Liang, M. Zhong, Y. H. Yu, S. Wu, and W. Wang. 2019. 'Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1', Oncogene , 38: 1256-68. Tables Tables 1 to 5 are available in the Supplementary Files section. Additional Declarations No competing interests reported. Supplementary Files Table1.xlsx Detailed information on the top 10 journals in terms of the number of published articles. Table2.xlsx Detailed information and influence of the top ten countries or regions in terms of the number of published articles. Table3.xlsx Detailed information of the top ten institutions in terms of the number of published articles. Table4.xlsx Detailed information of the author with the largest number of published articles Table5.xlsx Detailed information of the top ten most frequently cited documents Cite Share Download PDF Status: Under Review Version 1 posted Reviews received at journal 25 Apr, 2025 Reviewers agreed at journal 25 Apr, 2025 Reviewers agreed at journal 25 Apr, 2025 Reviewers invited by journal 25 Apr, 2025 Editor assigned by journal 25 Apr, 2025 Submission checks completed at journal 24 Apr, 2025 First submitted to journal 17 Apr, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6135216","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":448094348,"identity":"614e9afd-4e2b-4733-a7f2-1d4f97ffa850","order_by":0,"name":"Cong Xu","email":"","orcid":"","institution":"Dali University","correspondingAuthor":false,"prefix":"","firstName":"Cong","middleName":"","lastName":"Xu","suffix":""},{"id":448094350,"identity":"3ab9b280-45c8-4f11-9e39-b5aa3b48d8e7","order_by":1,"name":"Yonghong Xu","email":"","orcid":"","institution":"Banan Hospital Affiliated to Chongqing Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yonghong","middleName":"","lastName":"Xu","suffix":""},{"id":448094352,"identity":"900f82a7-3e68-446f-af62-ffadfcd80d9d","order_by":2,"name":"Guangming Wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYJCCAx8qJOQYDjA3HGBgYCZKB+PBGWcsjBkOMBKvhfkwb1tFYgNQCwNRWgzOr04AapFI7zt+sPEAQ4V1YgP72QP4tdx4u+HgnHMSuTPPAC1iOJOe2MCTl4BXi9mNsxsOvCmTyN1wAOS2tsOJDRI8BoS18LBJpBucfwjU8o8YLed7NxzkaZNIMLgBDgEitNjf4N0ADGQJw5k3gLYkHEs3buPJwa9Fsv/s5g8fKurk+c4nH/7wocZatp/9DH4tDBIJSBwQmw2/eiDgP0BQySgYBaNgFIx0AAAJtVhQqyoy8QAAAABJRU5ErkJggg==","orcid":"","institution":"Dali University","correspondingAuthor":true,"prefix":"","firstName":"Guangming","middleName":"","lastName":"Wang","suffix":""}],"badges":[],"createdAt":"2025-03-01 14:23:32","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6135216/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6135216/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":81552703,"identity":"2899c34b-e586-463d-b31f-ecfbebc742f2","added_by":"auto","created_at":"2025-04-28 13:04:22","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":110473,"visible":true,"origin":"","legend":"\u003cp\u003eFlowchart for the publication chosen included in this study.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/f61dc1584f26d86e42d73892.png"},{"id":81551383,"identity":"6e1d5ecb-c012-43e1-a668-897aa9df59d1","added_by":"auto","created_at":"2025-04-28 12:48:23","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":40292,"visible":true,"origin":"","legend":"\u003cp\u003eAnnual publications in the field of miRNA and Cervical cancer, 2010-2024\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/b71567d4949ee22d3cdda46f.png"},{"id":81552134,"identity":"33f64a18-7ec7-4dbe-8595-22a01be9c01c","added_by":"auto","created_at":"2025-04-28 12:56:23","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":3213675,"visible":true,"origin":"","legend":"\u003cp\u003eVisualization map of the journal density with the largest number of published articles in the field of cervical cancer and miRNA research.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/da070a2d61fa12892eb2c067.png"},{"id":81551384,"identity":"b15fe4c6-4e5c-4e85-aabc-fae5a299d92c","added_by":"auto","created_at":"2025-04-28 12:48:23","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":9042826,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information and influence of the top ten countries or regions in terms of the number of published articles\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/671b5824cd39941cf3476eb2.png"},{"id":81551381,"identity":"a2d8ab84-a731-4cf4-b5be-a4e320adb3e5","added_by":"auto","created_at":"2025-04-28 12:48:23","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":2239972,"visible":true,"origin":"","legend":"\u003cp\u003eBiblimetric for institutional collaboration and citation relationships\u003c/p\u003e","description":"","filename":"Figure5.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/2f7ae2c9564c5afdbb4326bf.png"},{"id":81552133,"identity":"aa213672-b963-4e58-a2fa-db14577ffc74","added_by":"auto","created_at":"2025-04-28 12:56:23","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":5462071,"visible":true,"origin":"","legend":"\u003cp\u003eCo-citation relationship diagram of keywords related to miRNA research in cervical cancer.\u003c/p\u003e","description":"","filename":"Figure6.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/6a9d65c953104bcc23f4625e.png"},{"id":81551389,"identity":"d1e6c269-cbe8-4f3e-b144-8911704bf3d0","added_by":"auto","created_at":"2025-04-28 12:48:23","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":1618794,"visible":true,"origin":"","legend":"\u003cp\u003eCluster map of keywords related to miRNA research in cervical cancer.\u003c/p\u003e","description":"","filename":"Figure7.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/af2a5c2924bc46127f17691d.png"},{"id":81552135,"identity":"619b9dbf-4eab-4404-9100-ce29ed436998","added_by":"auto","created_at":"2025-04-28 12:56:23","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":4871912,"visible":true,"origin":"","legend":"\u003cp\u003eThe correlation between different category clustering graphs and different institutions in different years\u003c/p\u003e","description":"","filename":"Figure8.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/78aad307e9921d637c1d3bc6.png"},{"id":81550636,"identity":"02034409-1886-4933-abff-8572c737a7af","added_by":"auto","created_at":"2025-04-28 12:40:23","extension":"png","order_by":9,"title":"Figure 9","display":"","copyAsset":false,"role":"figure","size":732613,"visible":true,"origin":"","legend":"\u003cp\u003eKey word highlighting chart and theme analysis of the research frontier\u003c/p\u003e","description":"","filename":"Figure9.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/d5906aeb6daed4768e43e408.png"},{"id":81551390,"identity":"7ab4d016-de1f-442d-9b21-cf4fcec195d1","added_by":"auto","created_at":"2025-04-28 12:48:23","extension":"png","order_by":10,"title":"Figure 10","display":"","copyAsset":false,"role":"figure","size":1023823,"visible":true,"origin":"","legend":"\u003cp\u003eThe relationship between miRNA and cited references of cervical cancer from 2010 to 2024.\u003c/p\u003e","description":"","filename":"Figure10.png","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/b9039cf92269d0fd42bb1047.png"},{"id":81553713,"identity":"e6c81166-5b88-494d-a7e5-bbd9ea4383ad","added_by":"auto","created_at":"2025-04-28 13:12:36","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":26766494,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/6421f32f-1c20-458a-828e-9121e49082e1.pdf"},{"id":81551379,"identity":"937fcf53-5ddb-4de5-bb90-c7d49aec2059","added_by":"auto","created_at":"2025-04-28 12:48:22","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":9935,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information on the top 10 journals in terms of the number of published articles.\u003c/p\u003e","description":"","filename":"Table1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/72c57c52484c154e95932bbe.xlsx"},{"id":81550615,"identity":"f6213762-772f-4795-ad2d-9aa57f7b42d4","added_by":"auto","created_at":"2025-04-28 12:40:22","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":9823,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information and influence of the top ten countries or regions in terms of the number of published articles.\u003c/p\u003e","description":"","filename":"Table2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/46dcb5d3c870267bd4891727.xlsx"},{"id":81550621,"identity":"814fb70b-078a-416a-a359-cfeebc14b838","added_by":"auto","created_at":"2025-04-28 12:40:23","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":684,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information of the top ten institutions in terms of the number of published articles.\u003c/p\u003e","description":"","filename":"Table3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/3f2bd093167ca6906c1cfe56.xlsx"},{"id":81550627,"identity":"71547504-ab98-4914-af5d-c86ece9078d5","added_by":"auto","created_at":"2025-04-28 12:40:23","extension":"xlsx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":10265,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information of the author with the largest number of published articles\u003c/p\u003e","description":"","filename":"Table4.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/1c661e0b25c79e0e518419d9.xlsx"},{"id":81552132,"identity":"9bce82db-d5d4-4349-ab7a-9b9a9bb42537","added_by":"auto","created_at":"2025-04-28 12:56:23","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":10479,"visible":true,"origin":"","legend":"\u003cp\u003eDetailed information of the top ten most frequently cited documents\u003c/p\u003e","description":"","filename":"Table5.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6135216/v1/fccd1d07bf67dd6a9c58d3f0.xlsx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Bibliometric Analysis of Research on cervical cancer and miRNAs from 2010 to 2024: Research Trends, HotSpots, and Prospects","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eCervical cancer(CC)constitutes a significant cause of morbidity and mortality globally and is the second most prevalent cancer among women, representing 14.1% of all female cancers and accounting for 7.1% of cancer-related deaths, as per the latest statistics. Among them, Asia and Africa are the two regions with the highest incidence and mortality of cervical cancer. (Moore \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2006\u003c/span\u003e)(\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gco.iarc.fr/today/en/dataviz/pie-prevalence?reset=1\u003c/span\u003e\u003cspan address=\"https://gco.iarc.fr/today/en/dataviz/pie-prevalence?reset=1\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eWhile incidence and mortality of cervical cancer have dramatically decreased in affluent countries over the past 50 years, the disease is still a major concern in developing nations, and medically underserved groups continue to have a high risk of getting cervical cancer.(Yuan et al. \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe underutilization of cervical cancer screening in these populations is one of the factors contributing to the higher risk. Through numerous clinical studies, it has been demonstrated that the treatment of early-stage cervical cancer should focus on significantly enhancing patients' quality of life (with particular emphasis on preserving reproductive function) and improving treatment accuracy while ensuring therapeutic efficacy. These advancements are primarily reflected in three key dimensions: the reduction of surgical extent, the minimization of invasive surgical techniques, and the precision of lymph node assessment.(Francoeur, Monk, and Tewari \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2025\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eEven with these alarming figures, the intricate pathological processes and molecular elements of cervical cancer continue to be a major threat to human health. The financial burden of cervical cancer in the area can be significantly reduced through the initiation of HPV-based initial screenings, effective handling of positive test outcomes, enhanced health education, and amalgamation of\u003c/p\u003e \u003cp\u003ediverse health services. Attaining extensive screening and adherence to treatment protocols can significantly lower the occurrence and death rate of cervical cancer. (Song et al. \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Vu et al. \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Zhao et al. \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e2022\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eMicroRNAs, known as miRNAs, are small non-coding RNAs that play regulatory roles in inhibiting or activating fundamental biological functions and cancer-related genes in humans. Increasing evidence suggests frequent dysregulation of miRNAs in cervical cancer. (Ba\u0026ntilde;uelos-Villegas, P\u0026eacute;rez-yP\u0026eacute;rez, and Alvarez-Salas \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2021\u003c/span\u003e)Innovative sequencing methods uncover a comprehensive view of the human transcriptome's makeup. MicroRNAs fulfill various roles in transcription, translation, and post-translation by interacting with lncRNAs, mRNAs, and cirRNAs. Previous research indicates miRNAs play a role in the development of various illnesses, such as breast cancer, prostate cancer, and cervical cancer. Hence, clarifying the function of miRNAs will enhance our comprehension of cervical cancer. miRNAs play a multifaceted role in cervical cancer, notably in its advancement, spread, resistance to treatment, regulation of HPV, and metabolic alteration. miRNAs hold as target molecules in the treatment and pioneering biomarkers for CC. Nonetheless, additional clinical research is required to enhance our comprehension of miRNAs' healing advantages in CC. (Heidari-Ezzati et al. \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eGaining a more profound insight into miRNA's role and patterns in cervical cancer studies aids scientists in comprehending fundamental, groundbreaking, and impactful research, and offers direction for emerging researchers in choosing research paths that hold promise and worth. Within this framework, our research aimed to perform an extensive bibliometric examination, enabling the identification of principal authors, organizations, scholarly articles, prevailing research directions and trends in miRNAs' role in cervical cancer development, collaborative trends among nations and journals, existing research focal points in existing literature, and prospective research directions in this field. (Zhang, Tan, et al. \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eTwo well-known visual analysis tools that bibliometric researchers can use to transform vast volumes of disorganized data into reliable and unbiased network maps are CiteSpace and VOSviewer. (Jiang et al. \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Zheng et al. \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Yan et al. \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e2021\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThrough a methodical examination of miRNA and cervical cancer studies, our aim is to uncover knowledge voids, underscore crucial discoveries, and establish a robust groundwork for upcoming research to enhance our grasp of cervical cancer genetics and refine therapies.\u003c/p\u003e"},{"header":"2. Data and method","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Data Policy and Screening Criteria\u003c/h2\u003e \u003cp\u003eWe conducted a comprehensive literature search using the Web of Science (WOS) Core Collection and PubMed, widely recognized and authoritative databases known for its extensive coverage of high-quality, peer-reviewed research across multiple disciplines. Its robust indexing and citation tracking capabilities make it particularly suitable for bibliometric analyses. The search focused on articles published between 2010 and 2024, as this period aligns with significant advancements in miRNA research and sequencing technologies, which have greatly expanded the understanding of miRNAs in cervical cancer. Earlier publications were excluded to ensure the analysis reflects the most recent and relevant scientific developments.\u003c/p\u003e \u003cp\u003eThe search strategy employed the following formula:\u003c/p\u003e \u003cp\u003e#1 ((ALL=(microRNA)) OR ALL=(miRNA)) OR TS=(mir))#2 ((ALL=(cervical cancer)) OR ALL=(cervical carcinoma)) OR ALL=(Carcinoma of Cervix)༉; #3: #1 AND #2. To ensure data accuracy and relevance, strict inclusion and exclusion criteria were applied. Only original research articles categorized as \"article\" were included, while reviews, conference papers, book chapters, editorial materials, and retracted publications were excluded. After applying these criteria, a total of 4034 documents were retrieved, downloaded, and stored in text format for further analysis. A comprehensive illustration of the research data collection process is presented in the data collection flowchart (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Methods\u003c/h2\u003e \u003cp\u003eBibliometric analysis is a quantitative method that uses mathematical and statistical techniques to examine patterns, trends, and relationships within academic literature. For this study, we employed two widely used tools: CiteSpace and VOSviewer. These tools were selected for their complementary strengths in visualizing and analyzing bibliometric networks, enabling a comprehensive exploration of research trends and collaborations.\u003c/p\u003e \u003cp\u003eVOSviewer is software for constructing and visualizing bibliometric networks. It represents entities such as countries, institutions, journals, authors, and keywords as nodes, with the size of each node reflecting its frequency or importance. Lines connecting nodes indicate co-occurrence or collaboration between entities. This tool is particularly effective for mapping large datasets and identifying key themes and clusters within the literature.\u003c/p\u003e \u003cp\u003eCiteSpace is another powerful tool for analyzing and visualizing trends in scientific literature. It uses algorithms to detect emerging trends, citation bursts, and thematic evolution over time. CiteSpace was chosen for its ability to generate dynamic visualizations of research landscapes, highlighting the temporal development of key topics and the influence of seminal works. Together, these tools provide a robust framework for understanding the structure and evolution of miRNA research in cervical cancer.\u003c/p\u003e \u003cp\u003eFinally, the volume and details of the publications were analyzed and charted using Microsoft Office Excel to supplement the visual and quantitative insights generated by CiteSpace and VOSviewer.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Result","content":"\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Outputs of Publications\u003c/h2\u003e \u003cp\u003eEvaluating the advancement of miRNA analysis in cervical cancer studies involved reviewing the publication records of 4034 WoSCC studies spanning 2010 to 2024, with the yearly publication data depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eGenerally, scholarly works indicate an expanding yet unpredictable pattern. Beginning in 2010 (n\u0026thinsp;=\u0026thinsp;56), there was a rise and zenith in the quantity of studies in 2020 (n\u0026thinsp;=\u0026thinsp;537), followed by a decrease in 2021 (n\u0026thinsp;=\u0026thinsp;478). Commencing in 2021, there was a steady annual decrease in the quantity of studies. (Figure \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e3.2 Density visualization of journals\u003c/h2\u003e \u003cp\u003eThe data analysis showed that Plos One and Scientific Reports had the highest number of publications in miRNA and cervical cancer research (n\u0026thinsp;=\u0026thinsp;114 and n\u0026thinsp;=\u0026thinsp;91, respectively), but Scientific Reports had relatively low total link strength (8108) and citations (1066). It shows that the influence of his article is limited. Oncology Letters (n\u0026thinsp;=\u0026thinsp;78) and Molecular Medicine Reports (n\u0026thinsp;=\u0026thinsp;65) showed very high total link strength (23,150 and 16,356, respectively), indicating that they occupy a central position in the miRNA research network. Although the number of citations (1394 and 1210) is not the highest. It is worth noting that Oncotarget (n\u0026thinsp;=\u0026thinsp;75), despite having been kicked out of the SCI, still shows a high number of citations (1771), reflecting its historical impact. Although Cell Death \u0026amp; Disease and BMC Cancer have fewer publications (n\u0026thinsp;=\u0026thinsp;65 and n\u0026thinsp;=\u0026thinsp;59, respectively), their studies may be of more reference value due to the high quality of the journals. Overall, Plos One, Oncotarget (historical data), and Biochemical and Biophysical Research Communications stand out in terms of impact, Oncology Letters, Oncology Reports and Molecular Medicine Reports are important sources for tumor-related miRNA studies. (Figure. 3, Table\u0026nbsp;1)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.3 Allocation of research according to country or region\u003c/h2\u003e \u003cp\u003eA multitude of countries and regions participated in the study to investigate the impact of miRNA on cervical cancer incidence. The table about this topic presents the top 10 regions/countries with the highest number of published research papers, including China (n\u0026thinsp;=\u0026thinsp;2879), the United States (n\u0026thinsp;=\u0026thinsp;421), India (n\u0026thinsp;=\u0026thinsp;129), and Japan (n\u0026thinsp;=\u0026thinsp;80). In terms of research influence, as measured by citation counts, China and the United States are at the forefront, with significantly higher citations compared to other countries. Specifically, China has accumulated 52,274 citations, the United States has garnered 7,080 citations, and India has received 1,823 citations. This demonstrates that a substantial number of researchers in China, the United States and India are actively engaged in exploring the role of miRNA in cervical cancer incidence (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThis data analysis reveals significant differences in the patterns of international research collaboration: The United States shows a high efficiency of international cooperation, and its total link strength (n\u0026thinsp;=\u0026thinsp;237) even exceeds that of China (n\u0026thinsp;=\u0026thinsp;210), which has the largest number of papers published, indicating that American researchers are more inclined to establish high-quality international cooperation networks, and the average international cooperation strength per paper is 0.56, much higher than that of China (0.07), highlighting its position as a global research collaborative hub. Although China's research output is dominated by 2879 articles (68% of the total), the low link strength to article ratio (0.07) reflects that the research is still dominated by domestic teams. Among the medium-sized countries, Canada performs well, with only 49 articles but a link strength of 67 (average article 1.37), reflecting its highly open scientific research ecology. On the other hand, Japan showed a relatively isolated trend, with only 38 link strengths of 80 articles, which may be affected by language barriers or localization research preferences. These findings suggest that the influence of scientific research depends not only on the quantity of output, but also on the quality of international cooperation, and countries need to develop differentiated cooperation strategies according to their own characteristics: China needs to enhance the depth of international cooperation while maintaining its scale advantage, the United States should maintain its open cooperation mechanism, and the \"small but fine\" model of countries such as Canada is worth learning from. It should be noted that the total link strength only reflects the quantitative characteristics of cooperation, and the specific quality of cooperation needs to be further analyzed in combination with indicators such as citation influence. (Table\u0026nbsp;2)\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.4 Co-authorship and citation relationships of institutions\u003c/h2\u003e \u003cp\u003eThe data presented in this table elucidates the differentiated research development models of leading medical colleges in China. In terms of research output, Zhengzhou University (n\u0026thinsp;=\u0026thinsp;80), Sun Yat-sen University (n\u0026thinsp;=\u0026thinsp;76), and Nanjing Medical University (n\u0026thinsp;=\u0026thinsp;72) ranked as the top three institutions, demonstrating a significant advantage in research volume. Although Tianjin Medical University published only 60 papers, it ranked first with 2,857 citations, achieving an impressive average of 47.6 citations per article, which underscores its commitment to high-quality research. Regarding international cooperation, Sun Yat-sen University leads with a total link strength of 450, while Wuhan University (363) and Zhejiang University (364) also exhibit strong performance, reflecting the extensive international collaboration networks established by these institutions. Notably, Shandong University (n\u0026thinsp;=\u0026thinsp;61; total link strenth: 306) and China Medical University (n\u0026thinsp;=\u0026thinsp;58; total link strenth: 317) primarily focus on domestic cooperation for their research endeavors. Conversely, Fudan University (n\u0026thinsp;=\u0026thinsp;57; total link strenth: 341) and Huazhong University of Science and Technology (n\u0026thinsp;=\u0026thinsp;56 ; total link strenth: 330) maintain a moderate scale while achieving balanced development in both research quality and international cooperation. These distinctions not only highlight the strategic positioning of each university but also reveal the diversified landscape of China's medical research ecosystem. Zhengzhou University exemplifies the \"scale-first\" development path, Tianjin Medical University reflects the \"quality-first\" research orientation, and Sun Yat-sen University showcases the successful implementation of \"international collaboration.\" Furthermore, the total link strength index effectively captures the level of engagement and hub status of each institution within the global scientific research network, providing a critical metric for assessing institutional internationalization. (Figure \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e, Table\u0026nbsp;3)\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e3.5 Research hotspots and evolutionary trends of miRNA in CC field\u003c/h2\u003e \u003cp\u003eWe choose \"keyword\" as the node type. 736 keywords were found, and the top 15 with the highest frequency are cervical cancer (n\u0026thinsp;=\u0026thinsp;839), expression (n\u0026thinsp;=\u0026thinsp;981), invasion (n\u0026thinsp;=\u0026thinsp;589), proliferation (n\u0026thinsp;=\u0026thinsp;555), metastasis (n\u0026thinsp;=\u0026thinsp;403), migration (n\u0026thinsp;=\u0026thinsp;395), growth (n\u0026thinsp;=\u0026thinsp;388), and microRNAs (n\u0026thinsp;=\u0026thinsp;344), progression (n\u0026thinsp;=\u0026thinsp;340), carcinoma (n\u0026thinsp;=\u0026thinsp;334), apoptosis (n\u0026thinsp;=\u0026thinsp;333), cell proliferation (n\u0026thinsp;=\u0026thinsp;296), cells (n\u0026thinsp;=\u0026thinsp;242), cancer (n\u0026thinsp;=\u0026thinsp;230), and human papillomavirus (n\u0026thinsp;=\u0026thinsp;227). In the keyword co-occurrence diagram, the larger the node, the higher the keyword co-occurrence frequency. (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eKeywords are the values used to identify specific data items in the literature, which are mainly used to briefly and accurately describe the topic of the article. We can understand the characteristics and evolution trend of the publication by analyzing the changes of keywords. This cluster chart summarizes the top 10 popular key research questions in the field. Keywords are divided into 10 different categories: #0 long non-coding, #1 DNA methylation, #2 cell proliferation, #3 cell proliferation, #4 gene, #5 head and neck squamous cell carcinoma, #6 nasopharyngeal carcinoma, #7 noncoding RNA, #8 cervical squamous cell carcinoma, #9 down regulation. (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eThrough the diachronic analysis of the keywords of miRNA research in cervical cancer from 2010 to 2024, we can clearly observe the dynamic evolution of research hotspots. In the early stage (2010\u0026ndash;2013), research focused on basic mechanism exploration. The high frequency of keywords such as \"cervical cancer\" (n\u0026thinsp;=\u0026thinsp;1839), \"expression\" (n\u0026thinsp;=\u0026thinsp;981), and \"human papillomavirus\" (n\u0026thinsp;=\u0026thinsp;227) reflects the researchers' focus on miRNA expression profiles and their relationship with HPV infection.\u003c/p\u003e \u003cp\u003eAs the study progressed (2014\u0026ndash;2017), the distribution of keywords showed a clear trend of clinical transformation. The frequency of biomarker\" (n\u0026thinsp;=\u0026thinsp;49) and \"chemoresistance\" (n\u0026thinsp;=\u0026thinsp;29) was significantly increased, indicating that research focus had shifted to the development of diagnostic markers and therapeutic targets. It is worth noting that the prominent performance of keywords such as \"epithelial mesenchymal transition\" (n\u0026thinsp;=\u0026thinsp;109) and \"migration\" (n\u0026thinsp;=\u0026thinsp;395) has revealed the central role of the EMT mechanism in tumor progression. The data of the last five years (2018\u0026ndash;2024) show the characteristics of multi-dimensional expansion. On the one hand, the rapid growth of non-coding RNA-related keywords such as \"circular RNA\" (n\u0026thinsp;=\u0026thinsp;75) and \"long noncoding RNA\" (n\u0026thinsp;=\u0026thinsp;53) reflects the rise of ceRNA regulatory network research. On the other hand, the emergence of emerging keywords such as \"immune infiltration\" (n\u0026thinsp;=\u0026thinsp;7) and \"oxidative stress\" (n\u0026thinsp;=\u0026thinsp;5) indicates the expansion of research into tumor microenvironment and systems biology. Of particular concern is the technology-driven keywords such as \"machine learning\" (n\u0026thinsp;=\u0026thinsp;3) and \"nanoparticles\" (n\u0026thinsp;=\u0026thinsp;3) that appear in 2023\u0026ndash;2024, indicating the application prospects of artificial intelligence and nanomedicine in this field. (Figure \u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e)\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eIt can also be analyzed from the keyword highlight chart. In recent years, the field of cervical cancer research has shown obvious stage evolution characteristics, from the early molecular mechanism exploration to clinical transformation application. Through the systematic analysis of the bibliometric data from 2010 to 2024, this study found that the research hotspots in this field experienced three significant development stages: the initial basic exploration period (2010\u0026ndash;2015) was characterized by broad spectrum keywords such as \"cancer\" (intensity 12.62) and \"gene\" (intensity 10.30). The subsequent technical development period (2016\u0026ndash;2020) focused on regulatory mechanisms such as \"overexpression\" (intensity 9.54) and epigenetic markers \"DNA methylation\" (intensity 8.15). At present, it has entered the clinical conversion period (2021\u0026ndash;2024), and with non-coding RNA research as the leading factor, the emergence intensity of \"circular rna\" has significantly increased from 8.83 in 2021 to 9.84 in 2022, with an annual growth rate of 11.4%, showing a strong momentum of development. Notably, \"squamous cell carcinoma\" showed the highest outburst intensity (15.57) between 2012 and 2016, reflecting the importance of HPV-associated squamous cell carcinoma mechanism research. Based on the prediction of the time series model, cervical cancer research in the next five years will focus on three directions: liquid biopsy technology combined with circRNA, spatial multi-omics integration research, and NCRNA-immunotherapy combination strategy. The development of these emerging fields is expected to promote the transformation of cervical cancer diagnosis and treatment mode from traditional morphological diagnosis to molecular typing and precision therapy, providing new opportunities to improve patient prognosis. (Figure \u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e9\u003c/span\u003e)\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e3.6 Co-authorship\u003c/h2\u003e \u003cp\u003eA total of 18,068 authors contributed to the study of microRNAs (miRNAs) in cervical cancer. Among them, the top ten authors with the highest number of published papers were identified.(Table\u0026nbsp;4)Through the comprehensive analysis of the data in this table, it can be seen that Chinese research institutions occupy a quantitative advantage in the field of cervical cancer miRNA research, but there is still room for international cooperation and quality improvement. Tang Hua༈n\u0026thinsp;=\u0026thinsp;50༉, Liu Min༈n\u0026thinsp;=\u0026thinsp;48༉ and Li Xin༈n\u0026thinsp;=\u0026thinsp;28༉from Tianjin Medical University formed the core research team, which has been cited 5444 times in total, and the cooperation intensity is 73, showing strong academic influence. Xie Xing༈n\u0026thinsp;=\u0026thinsp;22༉ and Lu Weiguo༈n\u0026thinsp;=\u0026thinsp;21༉from Zhejiang University have a small number of papers, but each paper has been cited more than 40 times and the cooperation intensity is as high as 110, showing high quality research results and extensive cooperation network. In contrast, although the cooperation intensity of Wang Wei༈n\u0026thinsp;=\u0026thinsp;49༉from Guangzhou, was only 6, indicating that his research was relatively isolated. It is worth noting that Steenbergen༈n\u0026thinsp;=\u0026thinsp;30༉ and Meijer༈n\u0026thinsp;=\u0026thinsp;25༉, scholars at the University Medical Center of Amsterdam have been cited an average of 735 times and maintain a high international cooperation relationship with a cooperation intensity of 47, providing a potential cooperation example for Chinese scholars. These findings suggest that while maintaining high output, Chinese teams need to focus on strengthening cooperation and communication with top teams in Europe and the United States, especially supporting scholars with weak cooperation networks but high output (such as Wang Wei), in order to further improve research quality and international influence.\u003c/p\u003e \u003cp\u003eThe H-index analyses of the table reveals the characteristics of multi-level differences in scientific research influence. First of all, Wang Jing from Peking University Sixth Hospital took a significant lead with the H-index of 105, indicating that his research results have outstanding academic influence, which is far higher than Tang Hua (49), the second ranking, and Meijer (58), the third scholar from the Netherlands. It is worth noting that two international scholars, Meijer (58) and Steenbergen (51), have excellent H-index performance, which corresponds to their high international cooperation strength (Total link strength of 72 and 22, respectively), reflecting the positive role of international cooperation in enhancing academic influence. In contrast, although Wang Wei of Guangzhou Medical University and Li Xin of Tianjin Medical University had a high number of publications (49 and 28 respectively), the H-index was only 5 and 4. This phenomenon of \"high yield and low citation\" may be due to the clinical application characteristics of their research directions or the junior qualifications of scholars. It is particularly noteworthy that Xie Xing and Lu Weiguo, two scholars from Zhejiang University, achieved a high H-index (40 and 39) while maintaining a moderate number of publications (22 and 21), reflecting stable research quality and sustained influence. These differences not only reflect the difference of individual research characteristics of scholars, but also reveal the shaping effect of disciplinary characteristics and international cooperation degree on academic influence. It is suggested that further research should be carried out in combination with factors such as scholars' career length and subject field characteristics.\u003c/p\u003e \u003cp\u003eWang, Wei, Guangzhou Medical University (This table system shows the core authors in the field of cervical cancer miRNA research and their academic influence pattern. The representative academic research results are in-depth analysis of the regulatory mechanism and clinical significance of miR-497 and miR-221-3p in cervical cancer. Studies have shown that miR-497 is significantly down-regulated in cervical cancer, and its low expression level is closely related to tumor progression and poor prognosis. Mechanistically, miR-497 inhibits proliferation and metastasis of tumor cells and induces apoptosis by targeting IGF-1R. On the other hand, we demonstrated for the first time that the exosome miR-221-3p promotes lymphatic metastasis through the VASH1/ERK/AKT signaling pathway. These findings not only reveal new molecular mechanisms, but also provide potential novel biomarkers and therapeutic targets for the early diagnosis and targeted therapy of cervical cancer. (Zhou et al. \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e2019\u003c/span\u003e;Luo et al. \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2013\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eTang, Hua(n\u0026thinsp;=\u0026thinsp;50)and Liu, Min (n\u0026thinsp;=\u0026thinsp;48), experts from Tianjin Medical University, systematically explained that different miRNAs (miR-346/miR-214/miR-372) regulate the diversity of cervical cancer malignant phenotypes through unique molecular mechanisms, revealing the AGO2-mediated amplification effect of miRNA network (miR-346). Cancer inhibition pathways that directly target key molecules of the cell cycle (miR-372) or signaling pathway nodes (miR-214) have also been identified, and directions for optimization of therapeutic strategies based on these findings (such as specific RNAi systems) have been explored. These results provide a multi-level theoretical basis for molecular typing and precise treatment of cervical cancer. (Guo et al. \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2015\u003c/span\u003e; Tian et al. \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e2011\u003c/span\u003e; Deng et al. \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2007\u003c/span\u003e; Yang et al. \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e2009\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe authors' joint effort is described by lines connecting nodes on a visual diagram. Tang Hua, Wang Wei and Liu Min ranked among the top three, indicating their lofty status in the research field. Small correlations were observed across different study groups, suggesting a lack of collaborative efforts among authors across numerous study subgroups.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e3.7 Analysis of co-citations of highly cited literature\u003c/h2\u003e \u003cp\u003eA total of 4034 articles were included in the analysis. The table presents the data of 10 most influential literatures in the field of miRNA research, and evaluates and analyzes them from two dimensions: Citations and Total link strength. In terms of citations, Tie et al. 's 2010 study topped the list with 384 citations, showing the wide influence of the literature in the academic community; Zhang (2016) and Hu (2010) ranked second and third with 281 and 259 citations, respectively. Notably, three of the top five citations were published between 2010 and 2011, suggesting that this period could be an important breakthrough period for miRNA research.(Table\u0026nbsp;5)\u003c/p\u003e \u003cp\u003eIn terms of total link strength, Hu (2010) has the most outstanding performance with a value of 86, which far exceeds other literatures, indicating that this study has a strong correlation and pivotal role in academic networks. It is found that earlier studies (2010\u0026ndash;2011) generally have higher link strength, such as Hu (2010), Wilting (2010), etc. This may reflect the widespread influence of these foundational works on subsequent research. Overall, the literature published in 2010\u0026ndash;2011 occupies a core position in the field of miRNA research, and these groundbreaking works are not only highly cited, but also play a key role in the academic network.\u003c/p\u003e \u003cp\u003eAmong them, Hu Xiaoxiao (2010) published in Cancer Research entitled \"A MicroRNA Expression Signature for Cervical Cancer Prognosis.\" The paper has been cited 259 times, making it the most cited article in the field. The second most-cited paper was Nehad M. (2011) \"miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway\" published on Cancer Research (n\u0026thinsp;=\u0026thinsp;253). In addition, Saskia M. Wilting's (2010) article \"Methylation-mediated silencing and tumor suppressive function of hsa-miR-124 in cervical cancer\" was published on Molecular Cancer (n\u0026thinsp;=\u0026thinsp;221). To further analyze the literature landscape, we used VOSviewer software to visualize the top 116 publications and their citation patterns. The visualization provides insights into the high-frequency and most influential articles in the field of cervical cancer and miRNA research, promoting a deeper understanding of key contributions to the field(Figure \u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e10\u003c/span\u003e,Table\u0026nbsp;6)\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eBibliometric analysis and scientific cartography have advanced significantly in recent years, reflecting the scientific community's growing interest in deriving insights from comprehensive assessments of research trends. Using bibliometric methods, our study explores the landscape of miRNA research in cervical cancer, highlighting key developments and trends in this field. Bibliometric analysis is valuable for identifying influential studies, mapping research networks, and providing a broad overview of the knowledge landscape within a specific domain. (Kang et al. \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Urasheva et al. \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Mutebi et al. \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e2022\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThis study is an original bibliometric analysis of 4034 publications on miRNAs in cervical cancer, published between 2010 and 2024. The analysis reveals a steady increase in research output over this period, with a peak in 2020 followed by a slight decline. The initial growth can be attributed to advancements in sequencing technologies and reduced costs, which facilitated miRNA research. The post-2020 decline may be linked to disruptions caused by the COVID-19 pandemic. The growing interest in miRNA research is driven by their potential roles in cervical cancer progression, diagnosis, and treatment, as well as the development of advanced molecular techniques. (Almobarak \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe average number of citations per article remains moderate, suggesting that this field holds significant potential for further exploration. Collaboration network analysis highlights the prominent role of Chinese institutions, which dominate in terms of publication volume. China, the United States, India, Japan, and Mexico are among the top five countries contributing to this field, both in terms of publications and citations. Leading Chinese institutions, such as Sun Yat-Sen University, Zhengzhou University, Shandong University, Nanjing Medical University, and Wuhan University, have made substantial contributions, reflecting the collaborative efforts of researchers in China. However, while Chinese institutions lead in productivity, the impact of research from other countries should not be overlooked, as they may produce fewer but more highly cited studies.\u003c/p\u003e \u003cp\u003eRegarding journal quality, Oncology Letters and Molecular Medicine Reports are among the most active and influential journals in this field, providing valuable platforms for researchers to share their findings.\u003c/p\u003e \u003cp\u003eEach country has made distinct contributions to the research on miRNA and cervical cancer, with China, the United States, and India being the three countries that have published the most studies and made the most significant contributions in this field.\u003c/p\u003e \u003cp\u003eChina has made remarkable progress in the field of cancer prevention and control, with the 5-year survival rate of cancer increasing from 30.9% in 2003\u0026ndash;2005 to 40.5% in 2012\u0026ndash;2015, mainly due to the national cancer screening program, the promotion of multidisciplinary collaborative diagnosis and treatment model, the clinical application of precision oncology technology, and the optimization of innovative drug research and development policies. (Weeden et al. \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)In order to continuously improve the level of cancer prevention and control, China has set the goal of raising the 5-year survival rate to 46.6% by 2030 through the Healthy China 2030 plan, and has adopted a series of measures, including improving the medical security system and promoting the accessibility of medical resources. (Lu et al. \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) At the technical level, professional organizations such as the Chinese Society of Clinical Oncology (CSCO) and the Chinese Anti-Cancer Association (CACA) have actively formulated diagnosis and treatment norms, promoted precision medicine to become the clinical standard, and supported the research of rare tumors and the transformation and application of artificial intelligence technology.(Diagnosis and Treatment Guidelines For Colorectal Cancer Working Group 2019; Lu et al. \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Fang et al. \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) However, China still faces social challenges in the field of cancer prevention and control, such as cultural attitudes (such as stigma and traditional filial piety affecting treatment decisions) and an aging population, which need to be addressed by strengthening popular science education and promoting preventive measures (such as tobacco control and vaccination). (Lu et al. \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) ( \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.csco.ac.cn/cat/1/show/2.html\u003c/span\u003e\u003cspan address=\"http://www.csco.ac.cn/cat/1/show/2.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThese comprehensive measures reflect China's systematic planning and firm determination to improve the level of cancer diagnosis and treatment. In addition, many Chinese scholars have conducted in-depth and continuous research on the diagnosis and treatment of cervical cancer in the direction of precision medicine and molecular biology, and certain achievements have been made in the research on miRNA in the direction of cervical cancer. For example, some scholars have found a new mechanism of miR-532-5p inhibiting tumor metastasis by regulating the accumulation of lipid drops (LDs): As a competitive RNA (ceRNA), LINC01410 adsorbs miR-532-5p and releases its inhibition of FASN, thereby promoting LDs accumulation and driving EMT and lymphangiogenesis. Moreover, the combination therapy of miR-532-5p and orlistat (FASN inhibitor) can significantly inhibit tumor growth and lymph node metastasis in vivo, providing a new basis for therapeutic strategies targeting the metabolism-metastasis axis. (Shang et al. \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) In addition, some scholars have found that LINC00885 plays a carcinogenic function in CC by regulating the miR-3150b-3p/BAZ2A axis. These findings suggest that LINC00885 may be a potentially promising therapeutic target for patients with CC. (Liu et al. \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) Some scholars have used novel methods to study the diagnosis of cervical cancer. Chen et al. developed a novel nucleic acid detection technology based on the split Cas12a system (SCas12a), which can detect miRNA and long RNA with high sensitivity without pre-amplification, and distinguish between mature miRNA and pre-miRNA. The system can specifically identify DNA and miRNA point mutations, and has been successfully applied to the detection of plasma miR-21 in cervical cancer patients. Combined with RPA, the sensitivity is up to amolar level, and HPV can be detected in clinical samples. (Chen et al. \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) These unique and advanced diagnostic approaches make it possible to augment current precision oncology practices in treatment decisions.\u003c/p\u003e \u003cp\u003eSimilarly, the United States, which has a lot of research achievements in the direction of miRNA, may be caused by mechanism exploration and technological invention as well as the open exploration of big data. In recent years, the field of cancer research has made revolutionary progress, mainly reflected in the following aspects: first, the significant reduction in the cost of sequencing technology and the maturity of technologies such as single-cell RNA sequencing, so that we can deeply understand the tumor and its microenvironment at the molecular level; Second, interdisciplinary fusion (such as the combination of nanotechnology, semiconductors, and biomedicine) has led to new diagnostic tools that significantly improve the ability of cells to accurately regulate. (Kelley et al. \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Kwon, Dudani, and Bhatia \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Kwong et al. \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Jonas et al. \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e2015\u003c/span\u003e; Huang et al. \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2015\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eMore importantly, studies based on the Cancer Genome Atlas and others have found that RNA technologies (including RNA interference drugs, mRNA vaccines, and CRISPR-Cas9 gene editing) are breaking through the limitations of traditional therapies, combining with nanomaterial delivery systems to provide new therapeutic possibilities for 80% of previously \"unpharmaceutical\" cancer targets. Together, these technological advances form a complete closed loop from basic research to clinical translation and are reshaping the cancer diagnosis and treatment landscape.(Tabernero et al. \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Liu et al. \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Zhen et al. \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Ehrke-Schulz et al. \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e2020\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe breakthrough of sequencing technology is particularly prominent, which can not only analyze multiple piece of information of tumor microenvironment at the same time, but also realize micro RNA and single-cell sequencing with the improvement of library technology, which provides valuable data for the comparative study before and after treatment. However, the emergence of massive heterogeneous data also brings standardization challenges, and there is an urgent need to establish unified data standards, electronic health system integration, and cloud data sharing. (Jaffee et al. \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e2017\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eIn addition to technological development, the huge prevalence and burden of India, which ranks third in the number of publications, is also a very important reason to promote the development of miRNA and cervical cancer. It is the second most common cancer among women in India. In 2018, the World Health Organization (WHO) reported an estimated 96,922 new cases of cervical cancer in India, with 60,078 deaths, representing 16.5% of the global burden.(Arbyn et al. \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2020\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe most frequently cited is \"A MicroRNA Expression Signature for Cervical Cancer Prognosis\" published in Cancer Research. This study has made an important breakthrough in predicting the prognosis of cervical cancer. By analyzing 102 cervical cancer samples, the research team found for the first time that two microRNAs, miR-200a and miR-9, can constitute effective prognostic markers, and established corresponding prediction models. Further mechanism studies showed that miR-200a could inhibit the metastasis of cervical cancer cells by synergistically regulating multiple transfer-related genes. (Hu et al. \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e2010\u003c/span\u003e) The second most-cited article was published in Cancer Research in 2010 and entitled \"MiR-218 inhibits gastric cancer invasion and metastasis by targeting Robo1 receptors.\" In this study, a dual miRNA prognostic model based on miR-200a and miR-9 was established for the first time by analyzing 102 cervical cancer samples, which is a difficult clinical problem to predict the prognosis of invasive cervical cancer. Studies have found that these two miRNAs can not only effectively predict patient survival, but also play a key regulatory role in the progression of cervical cancer: in particular, miR-200a regulates the motor metastasis ability of cancer cells by synergistically inhibiting multiple metastasis-related genes. (Tie et al. \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e2010\u003c/span\u003e) This study not only provides a new personalized prognostic assessment tool for cervical cancer (300,000 deaths per year worldwide), but also reveals the important value of miR-200a as a potential therapeutic target, providing a double breakthrough for improving the clinical diagnosis and treatment of cervical cancer. Provides a fundamental understanding of microrna biology, including their role in gene regulation and their impact on disease. The third most cited is \"Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer\" published in Molecular Cancer. This study demonstrated for the first time that hsa-miR-124 is silenced in cervical cancer due to DNA hypermethylation, and its methylation frequency significantly increased from 0% in normal tissue to 93% in cancer tissue. Mechanism studies showed that hsa-miR-124 inhibited the proliferation and migration of cancer cells by regulating the target gene IGFBP7, and demethylation treatment could restore its expression. The hsa-miR-124-1/-2 methylation detection protocol developed in this study showed good predictive value for cervical precancerous lesions. These findings not only reveal the key role of epigenetic regulation of hsa-miR-124 in the occurrence of cervical cancer, but also provide a new molecular marker for early diagnosis. (Wilting et al. \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e2010\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eIn conclusion, miRNAs play a crucial role in cervical cancer biology, influencing key processes such as gene regulation, tumor progression, and treatment response. In recent years, the regulatory role of non-coding RNA in the occurrence and development of cervical cancer has received increasing attention. Studies have shown that miRNA-centered non-coding RNA regulatory networks (including lncRNA and circRNA) show important value in the clinical diagnosis and treatment of cervical cancer. MiRNAs play a key role in cervical cancer progression and treatment response. (Pedroza-Torres et al. \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2014\u003c/span\u003e) For example, miR-200a and miR-9 can be used as biomarkers to predict radiotherapy sensitivity, while miR-421 and miR-23b/34a affect DNA damage response by regulating ATM/p53 pathway. (Hu et al. \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e2010\u003c/span\u003e) These findings suggest that miRNA is not only a potential target for cervical cancer treatment, but also its expression profile is expected to be used in clinical treatment decision-making. Further validation of these miRNA markers and development of targeted regulatory strategies are needed in the future.\u003c/p\u003e \u003cp\u003eIn addition, lncRNA (such as HOTAIR) and circRNA (such as CDR1as) can act as molecular sponges of miRNA to regulate the expression of downstream target genes through competitive binding. HOTAIR removes the inhibition of ZEB1 by adsorption of miR-23b-3p, promoting EMT and metastasis; CDR1as, by antagonizing miR-7, up-regulates EGFR expression and drives tumor proliferation. These findings not only revealed the key role of the lncRNA/circRNA-miRNA-mRNA regulatory axis in malignant phenotypes such as apoptosis escape, metastasis and spread of cervical cancer, but also provided new ideas for clinical practice. (Di Leva, Garofalo, and Croce \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Romero-Barrios et al. \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2018\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eOn the one hand, specific molecules in these regulatory networks, such as the circCDR1as/miR-7/EGFR pathway, are expected to be novel biomarkers for early diagnosis and subtype differentiation. On the other hand, dynamic monitoring of changes in these networks (such as HOTAIR/miR-23b-3p/ZEB1 fluctuations during treatment) can provide a basis for efficacy evaluation and resistance monitoring. Although the current complexity of ncRNA interactions poses challenges for clinical translation, these findings are expected to promote the development of precision diagnosis and treatment of cervical cancer in the future through multi-center validation of biomarkers and development of combined targeted therapy strategies (such as simultaneously targeting miRNAs and regulating Ncrnas). (Shen et al. \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e2020\u003c/span\u003e; Heidari-Ezzati et al. \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eFuture research should focus on elucidating the functional roles of miRNAs in cervical cancer and exploring their potential as diagnostic biomarkers and therapeutic targets. Such efforts could pave the way for improved clinical outcomes and more effective treatment strategies. (Virani et al. \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Zhang, Zheng, et al. \u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eKeyword analysis reveals the main themes and focus areas of miRNA and cervical cancer research. High-frequency keywords such as \"expression\" and \"invasion\". These mechanisms are essential for understanding the progression of cervical cancer and identifying potential therapeutic targets. The consistency between keyword trends and the research topics discussed in this study highlights the trends and hot spots for each stage of miRNA-based research in cervical cancer.\u003c/p\u003e \u003cp\u003eIn recent years, cervical cancer miRNA research has shown a significant trend from the basic mechanism to clinical transformation. Earlier studies (2010\u0026ndash;2013) focused on miRNA expression profiles and their association with HPV infection. The high-frequency keywords in this period were cervical cancer, expression, apoptosis, and HPV. Some scholars have investigated the characteristics of miRNA expression profiles in cervical cancer, indicating that aberrant miRNA expression may play a critical role in the development of cervical cancer. By conducting microarray chip analysis on cancerous and adjacent tissues from 13 HPV16/18-positive cervical cancer patients, it was found that 18 miRNAs were significantly upregulated (\u0026ge;\u0026thinsp;2-fold) and 19 miRNAs were significantly downregulated (\u0026le;\u0026thinsp;0.5-fold). Notably, these patients were infected with human papillomavirus (HPV) types 16 and/or 18. (Rao et al. \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2012\u003c/span\u003e) HPV facilitates malignant transformation through miRNA reprogramming. Research has demonstrated that the expression of 31 miRNAs undergoes continuous changes during the progression of cervical cancer. Among these, miR-29 suppresses cell proliferation and induces apoptosis by targeting YY1 (a transcription factor) and CDK6 (a cyclin-dependent kinase). Furthermore, the HPV oncogenic proteins E6/E7 may indirectly promote cellular malignant transformation by inhibiting miR-29. (Li et al. \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2011\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eAs biomarkers and therapeutic targets, miRNA is a marker for clinical translation of miRNA and cervical cancer studies (2014\u0026ndash;2017). At this time, the key words EMT, biomarker and chemoresistance are most used. At present, a substantial number of miRNAs can serve as potential targets for generating diverse biological profiles of cervical cancer cells. Some studies have demonstrated that the expression of miR-1246 is negatively correlated with both cervical cancer surgical outcomes and HPV16E6 infection status, indicating its potential utility as a diagnostic biomarker. (Yang et al. \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e2015\u003c/span\u003e) Furthermore, the expression profiles of a three-miRNA panel (hsa-miR-3154, hsa-miR-7-3p, and hsa-miR-600) have been established to predict patient survival. Specifically, hsa-miR-3154 and hsa-miR-7-3p are associated with poor prognosis and enriched in the mTOR signaling pathway, while hsa-miR-600 correlates with favorable prognosis and is enriched in the AMPK signaling pathway. (Zeng et al. \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e2018\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eFor instance, the oncogenic lncRNA PVT1 suppresses the expression of miR-195 by enhancing H3K27me3 modification and competitive binding within the miR-195 promoter region, thereby modulating paclitaxel-induced epithelial-mesenchymal transition (EMT) and chemoresistance. (Shen, Cheng, and Wang \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2017\u003c/span\u003e) Additionally, iASPP promotes EMT and cisplatin resistance through the upregulation of miR-20a in a p53-dependent manner, with its effects mediated via targeting FBXL5 and BTG3.\u003c/p\u003e \u003cp\u003e(Xiong et al. \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e2017\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eThe increased expression of serum miR-205, along with the discovery that miR-144 inhibits tumor proliferation and metastasis by targeting VEGFA/VEGFC, further expands the clinical application potential of miRNAs as therapeutic targets for cervical cancer diagnosis and treatment. (Tao et al. \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2018\u003c/span\u003e)These findings provide a critical theoretical foundation for elucidating the molecular mechanisms underlying cervical cancer and developing novel therapeutic strategies.\u003c/p\u003e \u003cp\u003eDuring this period, numerous studies have explored the molecular mechanisms underlying cervical cancer (CCa) progression, lymph node metastasis (LNM), and treatment resistance. Many scholars have conducted in-depth research on this topic.\u003c/p\u003e \u003cp\u003eThese investigations have identified several key regulatory molecules and their associated signaling pathways. Research has demonstrated that fatty acid-binding protein FABP5 is highly expressed in LNM, reprograms fatty acid metabolism to activate NF-κB signaling, thereby promoting epithelial-mesenchymal transition (EMT) and lymphangiogenesis. Meanwhile, miR-144-3p has been shown to inhibit the pro-metastatic effects of FABP5, and the fatty acid metabolic inhibitor orlistat effectively blocks this process. (Zhang, Liao, et al. \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e2020\u003c/span\u003e) Additionally, miR-532-5p suppresses LNM by regulating lipid droplet (LD) accumulation, while its competing endogenous RNA (ceRNA), LINC01410, upregulates fatty acid synthase (FASN) by sequestering miR-532-5p. (Shang et al. \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) The combination of LINC01410 and orlistat significantly inhibits tumor growth. In terms of non-coding RNA regulation, hsa_circ_0043280 functions as a tumor-suppressive circRNA by maintaining PAQR3 expression and inhibiting tumor metastasis through competitive binding to miR-203a-3p. (Zhang et al. 2021) Exosome-mediated delivery of miR-663b in the tumor microenvironment inhibits vinculin (VCL) expression and promotes angiogenesis, suggesting its potential as a target for anti-angiogenic therapy. (You et al. \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2021\u003c/span\u003e)Furthermore, lactic acid enhances the migration and invasion capabilities of HPV16-positive cervical cancer cells by upregulating miR-744 and partially downregulating the expression of the E6/E7 oncogenes via ARHGAP5 inhibition. (Li et al. \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e2019\u003c/span\u003e)\u003c/p\u003e \u003cp\u003eCollectively, these findings not only elucidate critical molecular mechanisms driving cervical cancer progression but also propose innovative therapeutic strategies based on miRNA, circRNA, and metabolic regulation, providing a theoretical foundation and potential targets for improving the prognosis of patients with cervical cancer.\u003c/p\u003e \u003cp\u003eIt is worth noting that the emergence of keywords such as \"immune infiltration\" (2022) and \"machine learning\" (2024) in recent years reflects the application potential of multi-omics integration and artificial intelligence in precision medicine. These trends suggest that future studies need to further explore the regulatory role of miRNA in immunotherapy resistance and develop targeted intervention strategies based on nanodelivery systems. In this short period of time, the keywords with high frequency are immune infiltration, oxidative stress and machine learning.\u003c/p\u003e \u003cp\u003eIn the field of machine learning, several scholars have conducted in-depth research by integrating the GEO and TCGA databases. Using a multi-omics analysis approach, they systematically investigated the molecular mechanisms underlying cervical cancer. Specifically, weighted gene co-expression network analysis (WGCNA) was employed to identify common differentially expressed genes (DEGs) associated with inflammatory bowel disease (IBD) and cervical cancer. Key pathways such as organelle fission, nuclear envelope, protein kinase activity, and HTLV-1 infection were identified. (Nguyen et al. \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) Key hub genes (CDK1, MAD2L1, CCNB1) showed high connectivity in PPI networks. Random forest analysis identified shared hub genes (NCAPH, UHRF1, CDCA2) between psoriasis and cervical cancer, enriched in mitosis and DNA methylation pathways. Immune infiltration was analyzed by CIBERSORT, while cMAP predicted potential drugs. Regulatory networks revealed miRNA/TF interactions with hub genes. (Liu et al. \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) The machine learning model validated the diagnostic potential of these hub genes (accuracy\u0026thinsp;\u0026gt;\u0026thinsp;0.90), providing a critical foundation for molecular classification and precision treatment of cervical cancer.\u003c/p\u003e \u003cp\u003eIn the realm of immunology, key mechanisms of immune escape mediated by non-coding RNA in cervical cancer have been elucidated. Research has demonstrated that long non-coding RNA LINC00240 is abnormally overexpressed in cervical cancer. Through competitive binding with miR-124-3p, it removes the inhibition of STAT3, further downregulating the expression of the natural killer (NK) cell activation ligand MICA. This leads to impaired cytotoxic function of NK T cells (NKT) and promotes tumor immune escape. Another long non-coding RNA, LINC01871, upregulates the expression of MAP3K2 and activates the MAPK signaling pathway by adsorbing miR-873-3p. (Li et al. \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e2025\u003c/span\u003e) Additionally, another study reveals that HPV16 oncogenic proteins E6/E7 remove their inhibitory effect on PD-L1 by downregulating miR-142-5p, thereby enhancing the immune escape capability of tumor cells. (Zhang, Li, et al. \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e2020\u003c/span\u003e) Overexpression of miR-142-5p effectively reverses this process and inhibits the growth of transplanted tumors. (Ling et al. \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) These findings comprehensively disclose multiple immune escape pathways regulated by non-coding RNA in cervical cancer, offering important theoretical foundations and potential therapeutic targets for developing novel strategies in non-coding RNA-based immunotherapy.\u003c/p\u003e"},{"header":"5. Limitation","content":"\u003cp\u003eThis study presents a bibliometric analysis of a foundational paper focusing on the role of miRNAs in cervical cancer. It outlines the advancements in this field by conducting a quantitative review of existing scholarly literature, aiming to provide guidance for future academic research. However, it is essential to acknowledge certain limitations. First, the exclusive reliance on the PubMed and Web of Science databases for data collection may introduce publication bias, potentially excluding studies that yield important results but are published in languages other than English. Additionally, various valuable sources of information, such as books, case reports, clinical trials, and meta-analyses, might be overlooked. Since the analysis was finalized in December 2024, several recent studies with significant findings may have been omitted from this review.\u003c/p\u003e"},{"header":"6. Conclusion","content":"\u003cp\u003eThis bibliometric analysis offers a systematic and comprehensive overview of research trends and hotspots related to microRNAs (miRNAs) in cervical cancer (CC) from 2010 to 2024. The study underscores a substantial increase in research output, driven by advancements in sequencing technologies and an enhanced understanding of the role of miRNAs in the progression, diagnosis, and treatment of CC. Key findings reveal major contributors, including China, the United States, and prestigious institutions such as Tianjin Medical University, as well as influential journals like PLOS ONE and Molecular Medicine Reports. Keyword analysis highlights miRNA-mediated mechanisms, such as gene expression regulation, cancer cell proliferation, migration, and apoptosis, emphasizing their potential as therapeutic targets and diagnostic biomarkers.\u003c/p\u003e \u003cp\u003eDespite these advancements, the translation of miRNA research into clinical applications remains limited. The relatively moderate citation rate of articles in this field indicates significant opportunities for further investigation. Future studies should focus on elucidating the functional roles of specific miRNAs in CC, validating their utility as diagnostic markers, and integrating novel research methodologies to develop miRNA-based therapies. Collaborative efforts among institutions and countries are crucial to overcoming existing challenges and advancing development in this area. This study not only provides a detailed depiction of the current state of miRNA research in CC but also establishes a foundation to guide future research and foster innovation for clinical applications.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eThe following abbreviations are used in this manuscript:\u003c/p\u003e\n\u003cp\u003eCC Cervical Cancer \u003c/p\u003e\n\u003cp\u003emiRNA microRNA \u003c/p\u003e\n\u003cp\u003eHPV Human Papillomavirus \u003c/p\u003e\n\u003cp\u003eWOS Web of Science \u003c/p\u003e\n\u003cp\u003eMSP Methylation-Specific PCR \u003c/p\u003e\n\u003cp\u003eIGFBP7 Insulin-like Growth Factor Binding Protein 7 \u003c/p\u003e\n\u003cp\u003eEMT Epithelial-Mesenchymal Transition \u003c/p\u003e\n\u003cp\u003elncRNA Long Non-coding RNA \u003c/p\u003e\n\u003cp\u003ecircRNA Circular RNA \u003c/p\u003e\n\u003cp\u003eRT-PCR Reverse Transcription Polymerase Chain Reaction \u003c/p\u003e\n\u003cp\u003eISH In Situ Hybridization \u003c/p\u003e\n\u003cp\u003eRPA Recombinase Polymerase Amplification \u003c/p\u003e\n\u003cp\u003eMDT Multidisciplinary Team \u003c/p\u003e\n\u003cp\u003eCACA Chinese Anti-Cancer Association \u003c/p\u003e\n\u003cp\u003eCSCO Chinese Society of Clinical Oncology \u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eContributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData curation, C.X.,Y.X.; writing\u0026mdash;original draft, C.X. ; software, C.X. ; writing\u0026mdash;review \u0026amp; editing, C.X. and G.W.; resources, G.W. All authors have read and agreed to the published version of the manuscript.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the Yunnan Province, Science and Technology Department of Yunnan Province (grant number 202001BA070001-133); the University Affiliated College, Key Construction Disciplines, 2021-2024, host, in research, 180,000; and the Joint Special Project of Local Universities of Yunnan Province (grant number 202001BA070001-156) ;Dali City Industrial Information and Science and Technology Bureau on the Dali City 2024 Science and Technology Plan project (grant number 2024KBG145)\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere is no conflict of interest to disclose.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and analyzed during thecurrent study are publicly available.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical Statement:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGiven that all data originated from online databases, patients\u0026apos; written informed consent was secured. Moreover, our research relied on open-source data, eliminating any pertinent ethical concerns.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eAlmobarak, F. 2024. \u0026apos;Bibliometric analysis of global research in palliative care for cervical cancer\u0026apos;, \u003cem\u003eFront Oncol\u003c/em\u003e, 14: 1432805.\u003c/li\u003e\n\u003cli\u003eArbyn, M., E. Weiderpass, L. Bruni, S. de Sanjos\u0026eacute;, M. Saraiya, J. Ferlay, and F. Bray. 2020. \u0026apos;Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis\u0026apos;, \u003cem\u003eLancet Glob Health\u003c/em\u003e, 8: e191-e203.\u003c/li\u003e\n\u003cli\u003eBa\u0026ntilde;uelos-Villegas, E. G., M. F. P\u0026eacute;rez-yP\u0026eacute;rez, and L. M. Alvarez-Salas. 2021. \u0026apos;Cervical Cancer, Papillomavirus, and miRNA Dysfunction\u0026apos;, \u003cem\u003eFront Mol Biosci\u003c/em\u003e, 8: 758337.\u003c/li\u003e\n\u003cli\u003eChen, Y., X. Wang, J. Zhang, Q. Jiang, B. Qiao, B. He, W. Yin, J. Qiao, and Y. Liu. 2024. \u0026apos;Split crRNA with CRISPR-Cas12a enabling highly sensitive and multiplexed detection of RNA and DNA\u0026apos;, \u003cem\u003eNat Commun\u003c/em\u003e, 15: 8342.\u003c/li\u003e\n\u003cli\u003eDeng, W. G., G. Jayachandran, G. Wu, K. Xu, J. A. Roth, and L. Ji. 2007. \u0026apos;Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells\u0026apos;, \u003cem\u003eJ Biol Chem\u003c/em\u003e, 282: 26460-70.\u003c/li\u003e\n\u003cli\u003eDi Leva, G., M. Garofalo, and C. M. Croce. 2014. \u0026apos;MicroRNAs in cancer\u0026apos;, \u003cem\u003eAnnu Rev Pathol\u003c/em\u003e, 9: 287-314.\u003c/li\u003e\n\u003cli\u003eDiagnosis, and Csococ Treatment Guidelines For Colorectal Cancer Working Group. 2019. \u0026apos;Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)\u0026apos;, \u003cem\u003eChin J Cancer Res\u003c/em\u003e, 31: 117-34.\u003c/li\u003e\n\u003cli\u003eEhrke-Schulz, E., S. Heinemann, L. Schulte, M. Schiwon, and A. Ehrhardt. 2020. \u0026apos;Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells\u0026apos;, \u003cem\u003eCancers (Basel)\u003c/em\u003e, 12.\u003c/li\u003e\n\u003cli\u003eFang, W., Z. Yu, C. Chen, G. Chen, K. Chen, J. Fu, Y. Han, X. Fu, J. Wang, T. Mao, Z. Gu, and N. Xu. 2024. \u0026apos;China Anti-Cancer Association Guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023)\u0026apos;, \u003cem\u003eMediastinum\u003c/em\u003e, 8: 27.\u003c/li\u003e\n\u003cli\u003eFrancoeur, A. A., B. J. Monk, and K. S. Tewari. 2025. \u0026apos;Treatment advances across the cervical cancer spectrum\u0026apos;, \u003cem\u003eNat Rev Clin Oncol\u003c/em\u003e, 22: 182-99.\u003c/li\u003e\n\u003cli\u003eGuo, J., J. Lv, M. Liu, and H. Tang. 2015. \u0026apos;miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy\u0026apos;, \u003cem\u003eJ Biol Chem\u003c/em\u003e, 290: 30342-50.\u003c/li\u003e\n\u003cli\u003eHeidari-Ezzati, S., P. Moeinian, B. Ahmadian-Nejad, F. Maghbbouli, S. Abbasi, M. Zahedi, H. Afkhami, A. Shadab, and N. Sajedi. 2024. \u0026apos;The role of long non-coding RNAs and circular RNAs in cervical cancer: modulating miRNA function\u0026apos;, \u003cem\u003eFront Cell Dev Biol\u003c/em\u003e, 12: 1308730.\u003c/li\u003e\n\u003cli\u003eHu, X., J. K. Schwarz, J. S. Lewis, Jr., P. C. Huettner, J. S. Rader, J. O. Deasy, P. W. Grigsby, and X. Wang. 2010. \u0026apos;A microRNA expression signature for cervical cancer prognosis\u0026apos;, \u003cem\u003eCancer Res\u003c/em\u003e, 70: 1441-8.\u003c/li\u003e\n\u003cli\u003eHuang, L., A. Holtzinger, I. Jagan, M. BeGora, I. Lohse, N. Ngai, C. Nostro, R. Wang, L. B. Muthuswamy, H. C. Crawford, C. Arrowsmith, S. E. Kalloger, D. J. Renouf, A. A. Connor, S. Cleary, D. F. Schaeffer, M. Roehrl, M. S. Tsao, S. Gallinger, G. Keller, and S. K. Muthuswamy. 2015. \u0026apos;Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids\u0026apos;, \u003cem\u003eNat Med\u003c/em\u003e, 21: 1364-71.\u003c/li\u003e\n\u003cli\u003eJaffee, E. M., C. V. Dang, D. B. Agus, B. M. Alexander, K. C. Anderson, A. Ashworth, A. D. Barker, R. Bastani, S. Bhatia, J. A. Bluestone, O. Brawley, A. J. Butte, D. G. Coit, N. E. Davidson, M. Davis, R. A. DePinho, R. B. Diasio, G. Draetta, A. L. Frazier, A. Futreal, S. S. Gambhir, P. A. Ganz, L. Garraway, S. Gerson, S. Gupta, J. Heath, R. I. Hoffman, C. Hudis, C. Hughes-Halbert, R. Ibrahim, H. Jadvar, B. Kavanagh, R. Kittles, Q. T. Le, S. M. Lippman, D. Mankoff, E. R. Mardis, D. K. Mayer, K. McMasters, N. J. Meropol, B. Mitchell, P. Naredi, D. Ornish, T. M. Pawlik, J. Peppercorn, M. G. Pomper, D. Raghavan, C. Ritchie, S. W. Schwarz, R. Sullivan, R. Wahl, J. D. Wolchok, S. L. Wong, and A. Yung. 2017. \u0026apos;Future cancer research priorities in the USA: a Lancet Oncology Commission\u0026apos;, \u003cem\u003eLancet Oncol\u003c/em\u003e, 18: e653-e706.\u003c/li\u003e\n\u003cli\u003eJiang, N., T. Yang, H. Han, J. Shui, M. Hou, W. Wei, G. Kumar, L. Song, C. Ma, X. Li, and Z. Ding. 2024. \u0026apos;Exploring Research Trend and Hotspots on Oxidative Stress in Ischemic Stroke (2001-2022): Insights from Bibliometric\u0026apos;, \u003cem\u003eMol Neurobiol\u003c/em\u003e, 61: 6200-16.\u003c/li\u003e\n\u003cli\u003eJonas, O., H. M. Landry, J. E. Fuller, J. T. Santini, Jr., J. Baselga, R. I. Tepper, M. J. Cima, and R. Langer. 2015. \u0026apos;An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors\u0026apos;, \u003cem\u003eSci Transl Med\u003c/em\u003e, 7: 284ra57.\u003c/li\u003e\n\u003cli\u003eKang, M., J. Qiu, H. Wei, and J. Li. 2023. \u0026apos;A bibliometric analysis of global research trends of inflammation in cervical cancer: A review\u0026apos;, \u003cem\u003eMedicine (Baltimore)\u003c/em\u003e, 102: e36598.\u003c/li\u003e\n\u003cli\u003eKelley, S. O., C. A. Mirkin, D. R. Walt, R. F. Ismagilov, M. Toner, and E. H. Sargent. 2014. \u0026apos;Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering\u0026apos;, \u003cem\u003eNat Nanotechnol\u003c/em\u003e, 9: 969-80.\u003c/li\u003e\n\u003cli\u003eKwon, E. J., J. S. Dudani, and S. N. Bhatia. 2017. \u0026apos;Ultrasensitive tumour-penetrating nanosensors of protease activity\u0026apos;, \u003cem\u003eNat Biomed Eng\u003c/em\u003e, 1.\u003c/li\u003e\n\u003cli\u003eKwong, G. A., G. von Maltzahn, G. Murugappan, O. Abudayyeh, S. Mo, I. A. Papayannopoulos, D. Y. Sverdlov, S. B. Liu, A. D. Warren, Y. Popov, D. Schuppan, and S. N. Bhatia. 2013. \u0026apos;Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease\u0026apos;, \u003cem\u003eNat Biotechnol\u003c/em\u003e, 31: 63-70.\u003c/li\u003e\n\u003cli\u003eLi, C., L. Jia, Y. Yu, and L. Jin. 2019. \u0026apos;Lactic acid induced microRNA-744 enhances motility of SiHa cervical cancer cells through targeting ARHGAP5\u0026apos;, \u003cem\u003eChem Biol Interact\u003c/em\u003e, 298: 86-95.\u003c/li\u003e\n\u003cli\u003eLi, Y., F. Wang, J. Xu, F. Ye, Y. Shen, J. Zhou, W. Lu, X. Wan, D. Ma, and X. Xie. 2011. \u0026apos;Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29\u0026apos;, \u003cem\u003eJ Pathol\u003c/em\u003e, 224: 484-95.\u003c/li\u003e\n\u003cli\u003eLi, Y., L. Wei, H. H. Zhang, H. F. Ci, and D. J. Li. 2025. \u0026apos;LINC01871 facilitates cervical cancer cell migration and immune escape by targeting miR-873-3p/MAP3K2 axis\u0026apos;, \u003cem\u003eKaohsiung J Med Sci\u003c/em\u003e, 41: e12948.\u003c/li\u003e\n\u003cli\u003eLing, J., Q. Sun, Q. Tian, H. Shi, H. Yang, and J. Ren. 2022. \u0026apos;Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis\u0026apos;, \u003cem\u003eArch Biochem Biophys\u003c/em\u003e, 731: 109449.\u003c/li\u003e\n\u003cli\u003eLiu, C., Q. Shi, X. Huang, S. Koo, N. Kong, and W. Tao. 2023. \u0026apos;mRNA-based cancer therapeutics\u0026apos;, \u003cem\u003eNat Rev Cancer\u003c/em\u003e, 23: 526-43.\u003c/li\u003e\n\u003cli\u003eLiu, L., P. Yin, R. Yang, G. Zhang, C. Wu, Y. Zheng, S. Wu, and M. Liu. 2024. \u0026apos;Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma\u0026apos;, \u003cem\u003eFront Immunol\u003c/em\u003e, 15: 1351908.\u003c/li\u003e\n\u003cli\u003eLiu, Y., J. Chen, L. Zhou, and C. Yin. 2022. \u0026apos;LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A\u0026apos;, \u003cem\u003eBiol Direct\u003c/em\u003e, 17: 4.\u003c/li\u003e\n\u003cli\u003eLu, Z., Y. Chen, D. Liu, X. Jiao, C. Liu, Y. Wang, Z. Zhang, K. Jia, J. Gong, Z. Yang, and L. Shen. 2023. \u0026apos;The landscape of cancer research and cancer care in China\u0026apos;, \u003cem\u003eNat Med\u003c/em\u003e, 29: 3022-32.\u003c/li\u003e\n\u003cli\u003eLuo, M., D. Shen, X. Zhou, X. Chen, and W. Wang. 2013. \u0026apos;MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor\u0026apos;, \u003cem\u003eSurgery\u003c/em\u003e, 153: 836-47.\u003c/li\u003e\n\u003cli\u003eMoore, D. H. 2006. \u0026apos;Cervical cancer\u0026apos;, \u003cem\u003eObstet Gynecol\u003c/em\u003e, 107: 1152-61.\u003c/li\u003e\n\u003cli\u003eMutebi, M., G. Lewison, A. Aggarwal, O. I. Alatise, C. Booth, M. Cira, S. Grover, O. Ginsburg, J. Gralow, S. Gueye, B. Kithaka, T. P. Kingham, L. Kochbati, J. Moodley, S. I. Mohammed, A. Mutombo, N. Ndlovu, C. Ntizimira, G. P. Parham, F. Walter, J. Parkes, D. Shamely, N. Hammad, J. Seeley, J. Torode, R. Sullivan, and V. Vanderpuye. 2022. \u0026apos;Cancer research across Africa: a comparative bibliometric analysis\u0026apos;, \u003cem\u003eBMJ Glob Health\u003c/em\u003e, 7.\u003c/li\u003e\n\u003cli\u003eNguyen, T. B., D. N. Do, M. L. Nguyen-Thi, H. Hoang-The, T. T. Tran, and T. Nguyen-Thanh. 2022. \u0026apos;Identification of potential crucial genes and key pathways shared in Inflammatory Bowel Disease and cervical cancer by machine learning and integrated bioinformatics\u0026apos;, \u003cem\u003eComput Biol Med\u003c/em\u003e, 149: 105996.\u003c/li\u003e\n\u003cli\u003ePedroza-Torres, A., E. L\u0026oacute;pez-Urrutia, V. Garc\u0026iacute;a-Castillo, N. Jacobo-Herrera, L. A. Herrera, O. Peralta-Zaragoza, C. L\u0026oacute;pez-Camarillo, D. C. De Leon, J. Fern\u0026aacute;ndez-Retana, J. F. Cerna-Cort\u0026eacute;s, and C. P\u0026eacute;rez-Plasencia. 2014. \u0026apos;MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance\u0026apos;, \u003cem\u003eMolecules\u003c/em\u003e, 19: 6263-81.\u003c/li\u003e\n\u003cli\u003eRao, Q., Q. Shen, H. Zhou, Y. Peng, J. Li, and Z. Lin. 2012. \u0026apos;Aberrant microRNA expression in human cervical carcinomas\u0026apos;, \u003cem\u003eMed Oncol\u003c/em\u003e, 29: 1242-8.\u003c/li\u003e\n\u003cli\u003eRomero-Barrios, N., M. F. Legascue, M. Benhamed, F. Ariel, and M. Crespi. 2018. \u0026apos;Splicing regulation by long noncoding RNAs\u0026apos;, \u003cem\u003eNucleic Acids Res\u003c/em\u003e, 46: 2169-84.\u003c/li\u003e\n\u003cli\u003eShang, C., Y. Li, T. He, Y. Liao, Q. Du, P. Wang, J. Qiao, and H. Guo. 2022. \u0026apos;The prognostic miR-532-5p-correlated ceRNA-mediated lipid droplet accumulation drives nodal metastasis of cervical cancer\u0026apos;, \u003cem\u003eJ Adv Res\u003c/em\u003e, 37: 169-84.\u003c/li\u003e\n\u003cli\u003eShen, C. J., Y. M. Cheng, and C. L. Wang. 2017. \u0026apos;LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells\u0026apos;, \u003cem\u003eJ Drug Target\u003c/em\u003e, 25: 637-44.\u003c/li\u003e\n\u003cli\u003eShen, S., S. Zhang, P. Liu, J. Wang, and H. Du. 2020. \u0026apos;Potential role of microRNAs in the treatment and diagnosis of cervical cancer\u0026apos;, \u003cem\u003eCancer Genet\u003c/em\u003e, 248-249: 25-30.\u003c/li\u003e\n\u003cli\u003eSong, L., X. Liang, M. Zhu, Q. Su, and F. Li. 2023. \u0026apos;Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023)\u0026apos;, \u003cem\u003eFront Immunol\u003c/em\u003e, 14: 1328103.\u003c/li\u003e\n\u003cli\u003eTabernero, J., G. I. Shapiro, P. M. LoRusso, A. Cervantes, G. K. Schwartz, G. J. Weiss, L. Paz-Ares, D. C. Cho, J. R. Infante, M. Alsina, M. M. Gounder, R. Falzone, J. Harrop, A. C. White, I. Toudjarska, D. Bumcrot, R. E. Meyers, G. Hinkle, N. Svrzikapa, R. M. Hutabarat, V. A. Clausen, J. Cehelsky, S. V. Nochur, C. Gamba-Vitalo, A. K. Vaishnaw, D. W. Sah, J. A. Gollob, and H. A. Burris, 3rd. 2013. \u0026apos;First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement\u0026apos;, \u003cem\u003eCancer Discov\u003c/em\u003e, 3: 406-17.\u003c/li\u003e\n\u003cli\u003eTao, P., H. Wen, B. Yang, A. Zhang, X. Wu, and Q. Li. 2018. \u0026apos;miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC\u0026apos;, \u003cem\u003eExp Ther Med\u003c/em\u003e, 15: 562-68.\u003c/li\u003e\n\u003cli\u003eTian, R. Q., X. H. Wang, L. J. Hou, W. H. Jia, Q. Yang, Y. X. Li, M. Liu, X. Li, and H. Tang. 2011. \u0026apos;MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis\u0026apos;, \u003cem\u003eJ Biol Chem\u003c/em\u003e, 286: 25556-63.\u003c/li\u003e\n\u003cli\u003eTie, J., Y. Pan, L. Zhao, K. Wu, J. Liu, S. Sun, X. Guo, B. Wang, Y. Gang, Y. Zhang, Q. Li, T. Qiao, Q. Zhao, Y. Nie, and D. Fan. 2010. \u0026apos;MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor\u0026apos;, \u003cem\u003ePLoS Genet\u003c/em\u003e, 6: e1000879.\u003c/li\u003e\n\u003cli\u003eUrasheva, Z. U., G. B. Kabdrakhmanova, A. P. Yermagambetova, A. B. Utegenova, N. A. Seitmaganbetova, O. M. Aliyev, S. S. Kurmangaliyeva, N. K. Kenzhina, Y. Z. Kurmambayev, and A. A. Khamidulla. 2024. \u0026apos;Bibliometric Analysis of the Role of Occludin in the Pathogenesis of Stroke\u0026apos;, \u003cem\u003eOxid Med Cell Longev\u003c/em\u003e, 2024: 2121733.\u003c/li\u003e\n\u003cli\u003eVirani, S. S., A. Alonso, H. J. Aparicio, E. J. Benjamin, M. S. Bittencourt, C. W. Callaway, A. P. Carson, A. M. Chamberlain, S. Cheng, F. N. Delling, M. S. V. Elkind, K. R. Evenson, J. F. Ferguson, D. K. Gupta, S. S. Khan, B. M. Kissela, K. L. Knutson, C. D. Lee, T. T. Lewis, J. Liu, M. S. Loop, P. L. Lutsey, J. Ma, J. Mackey, S. S. Martin, D. B. Matchar, M. E. Mussolino, S. D. Navaneethan, A. M. Perak, G. A. Roth, Z. Samad, G. M. Satou, E. B. Schroeder, S. H. Shah, C. M. Shay, A. Stokes, L. B. VanWagner, N. Y. Wang, and C. W. Tsao. 2021. \u0026apos;Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association\u0026apos;, \u003cem\u003eCirculation\u003c/em\u003e, 143: e254-e743.\u003c/li\u003e\n\u003cli\u003eVu, M., J. Yu, O. A. Awolude, and L. Chuang. 2018. \u0026apos;Cervical cancer worldwide\u0026apos;, \u003cem\u003eCurr Probl Cancer\u003c/em\u003e, 42: 457-65.\u003c/li\u003e\n\u003cli\u003eWeeden, C. E., W. Hill, E. L. Lim, E. Gr\u0026ouml;nroos, and C. Swanton. 2023. \u0026apos;Impact of risk factors on early cancer evolution\u0026apos;, \u003cem\u003eCell\u003c/em\u003e, 186: 1541-63.\u003c/li\u003e\n\u003cli\u003eWilting, S. M., R. A. van Boerdonk, F. E. Henken, C. J. Meijer, B. Diosdado, G. A. Meijer, C. le Sage, R. Agami, P. J. Snijders, and R. D. Steenbergen. 2010. \u0026apos;Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer\u0026apos;, \u003cem\u003eMol Cancer\u003c/em\u003e, 9: 167.\u003c/li\u003e\n\u003cli\u003eXiong, Y., F. Sun, P. Dong, H. Watari, J. Yue, M. F. Yu, C. Y. Lan, Y. Wang, and Z. B. Ma. 2017. \u0026apos;iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling\u0026apos;, \u003cem\u003eJ Exp Clin Cancer Res\u003c/em\u003e, 36: 48.\u003c/li\u003e\n\u003cli\u003eYan, W. T., S. Lu, Y. D. Yang, W. Y. Ning, Y. Cai, X. M. Hu, Q. Zhang, and K. Xiong. 2021. \u0026apos;Research trends, hot spots and prospects for necroptosis in the field of neuroscience\u0026apos;, \u003cem\u003eNeural Regen Res\u003c/em\u003e, 16: 1628-37.\u003c/li\u003e\n\u003cli\u003eYang, Y., Y. J. Xie, Q. Xu, J. X. Chen, N. C. Shan, and Y. Zhang. 2015. \u0026apos;Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance\u0026apos;, \u003cem\u003eGynecol Oncol\u003c/em\u003e, 138: 683-8.\u003c/li\u003e\n\u003cli\u003eYang, Z., S. Chen, X. Luan, Y. Li, M. Liu, X. Li, T. Liu, and H. Tang. 2009. \u0026apos;MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells\u0026apos;, \u003cem\u003eIUBMB Life\u003c/em\u003e, 61: 1075-82.\u003c/li\u003e\n\u003cli\u003eYou, X., W. Sun, Y. Wang, X. Liu, A. Wang, L. Liu, S. Han, Y. Sun, J. Zhang, L. Guo, and Y. Zhang. 2021. \u0026apos;Cervical cancer-derived exosomal miR-663b promotes angiogenesis by inhibiting vinculin expression in vascular endothelial cells\u0026apos;, \u003cem\u003eCancer Cell Int\u003c/em\u003e, 21: 684.\u003c/li\u003e\n\u003cli\u003eYuan, M., X. Zhao, H. Wang, S. Hu, and F. Zhao. 2023. \u0026apos;Trend in Cervical Cancer Incidence and Mortality Rates in China, 2006-2030: A Bayesian Age-Period-Cohort Modeling Study\u0026apos;, \u003cem\u003eCancer Epidemiol Biomarkers Prev\u003c/em\u003e, 32: 825-33.\u003c/li\u003e\n\u003cli\u003eZeng, Y., K. X. Wang, H. Xu, and Y. Hong. 2018. \u0026apos;Integrative miRNA analysis identifies hsa-miR-3154, hsa-miR-7-3, and hsa-miR-600 as potential prognostic biomarker for cervical cancer\u0026apos;, \u003cem\u003eJ Cell Biochem\u003c/em\u003e, 119: 1558-66.\u003c/li\u003e\n\u003cli\u003eZhang, C., Y. Liao, P. Liu, Q. Du, Y. Liang, S. Ooi, S. Qin, S. He, S. Yao, and W. Wang. 2020. \u0026apos;FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism\u0026apos;, \u003cem\u003eTheranostics\u003c/em\u003e, 10: 6561-80.\u003c/li\u003e\n\u003cli\u003eZhang, C., P. Liu, J. Huang, Y. Liao, C. Pan, J. Liu, Q. Du, T. Liu, C. Shang, S. Ooi, R. Chen, M. Xia, H. Jiang, M. Xu, Q. Zou, Y. Zhou, H. Huang, Y. Pan, L. Yuan, W. Wang, and S. Yao. 2021. \u0026apos;Circular RNA hsa_circ_0043280 inhibits cervical cancer tumor growth and metastasis via miR-203a-3p/PAQR3 axis\u0026apos;, \u003cem\u003eCell Death Dis\u003c/em\u003e, 12: 888.\u003c/li\u003e\n\u003cli\u003eZhang, M., Z. Zheng, S. Wang, R. Liu, M. Zhang, Z. Guo, H. Wang, and W. Tan. 2024. \u0026apos;The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer\u0026apos;, \u003cem\u003eCancer Drug Resist\u003c/em\u003e, 7: 30.\u003c/li\u003e\n\u003cli\u003eZhang, Y., X. Li, J. Zhang, and H. Liang. 2020. \u0026apos;Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis\u0026apos;, \u003cem\u003eCancer Lett\u003c/em\u003e, 474: 63-73.\u003c/li\u003e\n\u003cli\u003eZhang, Y., Y. T. Tan, M. J. Wang, L. Li, J. F. Huang, and S. C. Wang. 2024. \u0026apos;Bibliometric analysis of PTEN in neurodevelopment and neurodegeneration\u0026apos;, \u003cem\u003eFront Aging Neurosci\u003c/em\u003e, 16: 1390324.\u003c/li\u003e\n\u003cli\u003eZhao, S., L. Huang, P. Basu, E. J. Domingo, W. Supakarapongkul, W. Y. Ling, D. Ocviyanti, R. Rezhake, Y. Qiao, E. H. Tay, and F. Zhao. 2022. \u0026apos;Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries\u0026apos;, \u003cem\u003eCancer Lett\u003c/em\u003e, 525: 22-32.\u003c/li\u003e\n\u003cli\u003eZhen, S., R. Qiang, J. Lu, X. Tuo, X. Yang, and X. Li. 2023. \u0026apos;CRISPR/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer\u0026apos;, \u003cem\u003eJ Med Virol\u003c/em\u003e, 95: e28144.\u003c/li\u003e\n\u003cli\u003eZheng, S. Y., X. M. Hu, K. Huang, Z. H. Li, Q. N. Chen, R. H. Yang, and K. Xiong. 2022. \u0026apos;Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going\u0026apos;, \u003cem\u003eFront Surg\u003c/em\u003e, 9: 1025557.\u003c/li\u003e\n\u003cli\u003eZhou, C. F., J. Ma, L. Huang, H. Y. Yi, Y. M. Zhang, X. G. Wu, R. M. Yan, L. Liang, M. Zhong, Y. H. Yu, S. Wu, and W. Wang. 2019. \u0026apos;Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1\u0026apos;, \u003cem\u003eOncogene\u003c/em\u003e, 38: 1256-68.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 5 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"discover-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"dion","sideBox":"Learn more about [Discover Oncology](https://www.springer.com/12672)","snPcode":"","submissionUrl":"","title":"Discover Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Discover Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Bibliometrics, cervical cancer, VOSviewer, miRNA, CiteSpace","lastPublishedDoi":"10.21203/rs.3.rs-6135216/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6135216/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground and Purpose\u003c/h2\u003e \u003cp\u003eMicroRNAs (miRNAs) play multifaceted roles in cervical cancer therapy, including regulating cancer progression, metastasis, drug resistance, HPV control, and metabolic alterations. This study aims to provide a comprehensive bibliometric analysis of the existing literature on miRNAs in cervical cancer, offering insights into research trends, key contributors, and emerging themes to guide future investigations and enhance therapeutic strategies.\u003c/p\u003e\u003ch2\u003eMethod\u003c/h2\u003e \u003cp\u003eWe conducted a systematic search of the Web of Science and PubMed database for literature on miRNAs in cervical cancer published between January 2010 and December 2024. A total of 4034 records were retrieved and analyzed using VOSviewer and CiteSpace software for bibliometric visualization and trend analysis.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eOver the past fifteen years, research on miRNA in cervical cancer showed a significant upward trend before 2020, and then gradually declined starting from 2021. The analysis reveals that Tang and Hua are the most active authors, and China is the most influential country. \"Plos One\" is the journal that publishes the most articles. Besides, Tianjin Medical University is the most productive institution. The top three high-frequency keywords are \"cervical cancer\", \"expression\" and \"invasion\". Recent keyword and literature analysis indicates that the most notable feature of the current research is the deep integration of basic research and clinical application. Particularly, the cross-integration of non-coding RNA network research with emerging technologies such as nanotechnology and artificial intelligence is promoting the precise diagnosis and treatment system of cervical cancer. These findings highlight the interest in understanding the miRNA-mediated pathways and their clinical significance in cervical cancer.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThis bibliometric analysis provides a comprehensive overview of the research landscape on miRNAs in cervical cancer, identifying key contributors, institutions, and emerging trends. While the study does not predict the future direction of cervical cancer treatment, it offers valuable insights into the current state of research and potential areas for further exploration. The findings underscore the importance of continued investigation into miRNA mechanisms and their therapeutic applications to advance cervical cancer management.\u003c/p\u003e","manuscriptTitle":"Bibliometric Analysis of Research on cervical cancer and miRNAs from 2010 to 2024: Research Trends, HotSpots, and Prospects","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-04-28 12:40:18","doi":"10.21203/rs.3.rs-6135216/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorInvitedReview","content":"","date":"2025-04-25T15:16:33+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"48237324209694405868594513466917489289","date":"2025-04-25T14:03:55+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"168211666369017291540596643070522063125","date":"2025-04-25T09:21:00+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-04-25T07:34:17+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-04-25T07:34:08+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-04-24T12:22:52+00:00","index":"","fulltext":""},{"type":"submitted","content":"Discover Oncology","date":"2025-04-17T15:17:38+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"discover-oncology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"dion","sideBox":"Learn more about [Discover Oncology](https://www.springer.com/12672)","snPcode":"","submissionUrl":"","title":"Discover Oncology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Discover Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5be9484c-eba4-4b4e-a215-4cd9ab1aba1d","owner":[],"postedDate":"April 28th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2025-06-27T12:53:25+00:00","versionOfRecord":[],"versionCreatedAt":"2025-04-28 12:40:18","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6135216","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6135216","identity":"rs-6135216","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}